Press Releases
06.21.17
Adimab Provides Mid-Year Update on 2017 Partnership Activity

Lebanon, New Hampshire – June 21, 2017 – Adimab, LLC, the global leader in the discovery and optimization of fully human monoclonal and bispecific antibodies, today announced that in the first half of 2017 it entered into agreements with six new companies. In addition, Adimab announced the expansion of four of its current partnerships and the achievement of over 20 technical and development milestones across multiple existing collaborations.

Over the past eight years, Adimab has entered into 50 partnerships for the discovery of therapeutic IgGs and bispecific antibodies, resulting in 175 therapeutic programs generated using the Adimab Platform. The most advanced program with partner Arsanis is currently in Phase II clinical trials. New alliances for 2017 include Anokion, Moderna Therapeutics, Mapp Biopharmaceutical, and Pionyr Immunotherapeutics, among others. In addition, Adimab expanded its collaborations with Celgene, Sanofi, and several others.

“Surface Oncology has been working with Adimab since its formation and we are about to start our seventh therapeutic program with them,” added Scott Chappel, Chief Technology Officer at Surface Oncology. “We know there are many options to discover antibodies but Adimab continues to perform beyond expectations. We are thrilled with our long-standing relationship with Adimab and they have made a big contribution to our success.”

"At Scholar Rock, we are committed to having the best possible therapeutic product candidates before investing millions of dollars in clinical development," said Nagesh Mahanthappa, Chief Executive Officer and President of Scholar Rock. "Adimab was able to quickly generate antibodies that meet our desired selectivity requirements on complex targets, and we look forward to other future successes together."

“We have focused on being the high-quality and not the low-cost provider - over the past eight years that has proven to be a very successful strategy,” commented Tillman Gerngross, Chief Executive Officer and Co-Founder of Adimab. “Many of our collaborators come to us with programs that have failed with other technologies and we get them back on track - when you commit to spending tens of millions of dollars on clinical trials you want to make sure that you are moving the best molecules forward. All our deals are structured that we win when our partners win - we are thrilled by their success.”

Adimab partners have exercised a total of six commercial licenses in the first half of 2017, including Biogen, Celgene, Checkpoint (a Fortress Biotech company), Potenza, and Surface Oncology.

Adimab has established partnerships with 50 pharmaceutical and biotechnology companies. The Adimab technology has been transferred and implemented at Merck, Novo Nordisk, Biogen and GSK. Funded discovery partners include leading pharmaceutical companies, such as Novo Nordisk, Biogen, GSK, Roche, Novartis, Eli Lilly, Genentech, Celgene, Gilead, Kyowa Hakko Kirin, Sanofi and others. Adimab has also partnered with many mid-size and early-stage venture-backed companies, including Merrimack, Five Prime, Jounce, Innovent, Alector, Acceleron, Surface Oncology, Potenza, Arsanis and others.

02.27.17
Arsanis and Adimab Enter Into License Agreement to Target Respiratory Syncytial Virus (RSV) With Monoclonal Antibodies

Waltham, MA, US, Veinna, Austria, and Lebanon, NH, US – February 27, 2017 – Arsanis, Inc., a clinical-stage biopharmaceutical company developing targeted monoclonal antibodies for pre-emptive and post-infection treatment of serious infectious diseases, and Adimab, LLC, the global leader in the discovery and optimization of fully human monoclonal and bispecific antibodies, announced today they have entered into an agreement under which Arsanis has secured the exclusive, worldwide license to antibodies targeting respiratory syncytial virus (RSV) that were discovered by Adimab. Arsanis will initially focus on the selection of a lead RSV antibody candidate and has received a grant of up to $9.3 million from the Bill & Melinda Gates Foundation to advance the selected antibody to IND filing.

"Arsanis' partnerships with Adimab and the Gates Foundation will allow us to apply our deep expertise in the discovery and development of anti-infective antibodies to advance highly potent human monoclonal antibodies for the prevention of RSV infection," said Rene Russo, Pharm.D., BCPS, President and Chief Executive Officer, Arsanis. "We believe this approach has the potential to address a significant global need for effective and accessible RSV therapeutics in both developed and developing countries."

Under the agreement with Adimab, Arsanis has exclusively licensed a panel of RSV antibodies for the purpose of evaluating and selecting the best therapeutic leads under an exclusive global development and commercialization license. Adimab will be entitled to receive license fees and development milestones, as well as a royalty on net sales.

"We are very pleased that Arsanis and the Gates Foundation are collaborating on this important program. Through our B cell isolation approach, Adimab has identified highly potent antibodies against a number of infectious disease targets. The RSV antibodies licensed to Arsanis include some of the most potent RSV neutralizers reported to date," said Guy Van Meter, VP of Business Development at Adimab. "This new agreement expands an already successful relationship with Arsanis, under which Arsanis’ lead program ASN100 for S. aureus pneumonia, currently in a Phase 2 clinical study, was discovered."

About Respiratory Syncytial Virus (RSV)
RSV is a highly contagious virus that causes infections in both the upper and lower respiratory tract. RSV infects nearly every child at least once by the age of two years and is a major cause of hospitalization due to respiratory infection in children, the elderly, and immunocompromised patients. RSV infection typically results in cold-like symptoms but can lead to more serious respiratory illnesses such as croup, pneumonia, bronchiolitis, and in extreme cases, death. RSV infection in the pediatric and adult populations account for more than 300,000 hospitalizations per year in the U.S. In the developing world, RSV is responsible for 30 million cases of acute respiratory tract infection and 200,000 deaths per year. As a result, there is a significant need for novel therapeutics to prevent RSV infection.

02.23.17
Adimab Publishes Biophysical Performance Metrics that Predict Drug-like Properties of Antibody-based Therapeutics

Lebanon, New Hampshire – February 23, 2017 – Adimab, LLC, the global leader in the discovery and optimization of fully human monoclonal and bispecific antibodies, today announced the publication of a study focused on the biophysical characterization of 137 clinical-stage and approved antibody drugs. The research was published in the Proceedings of the National Academy of Sciences (PNAS).

"Developability of antibody therapeutics has been an important focus at Adimab," stated Yingda Xu, Director of Protein Analytics at Adimab. "Many antibodies enter clinical testing yet fail to become drugs because of poly-specificity, expressibility, and aggregation issues. Our work provides practical guidelines for applying biophysical assays early in the antibody discovery process to focus on leads that are likely to succeed."

"We have had Lipinski’s rule of five providing general guidance of what successful small-molecule drugs typically look like. However, up to this point, we have not had such a rule set for antibody-based therapeutics. This work begins to close that gap," commented Dane Wittrup, co-founder of Adimab.

"Adimab spends more than $5 million annually to advance new technologies and capabilities. One of our focus areas over the past couple of years has been developability and understanding the reasons why antibodies fail in development. This publication helps to provide a framework for assessing the likelihood of an antibody or bispecific molecule becoming an actual drug," said Tillman Gerngross, co-founder and CEO of Adimab.

The abstract of the PNAS paper entitled "Biophysical properties of the clinical-stage antibody landscape" reads:

Antibodies are a highly successful class of biological drugs, with over 50 such molecules approved for therapeutic use and hundreds more currently in clinical development. Improvements in technology for the discovery and optimization of high-potency antibodies have greatly increased the chances for finding binding molecules with desired biological properties; however, achieving drug-like properties at the same time is an additional requirement that is receiving increased attention. In this work, we attempt to quantify the historical limits of acceptability for multiple biophysical metrics of “developability.” Amino acid sequences from 137 antibodies in advanced clinical stages, including 48 approved for therapeutic use, were collected and used to construct isotype-matched IgG1 antibodies, which were then expressed in mammalian cells. The resulting material for each source antibody was evaluated in a dozen biophysical property assays. The distributions of the observed metrics are used to empirically define boundaries of drug-like behavior that can represent practical guidelines for future antibody drug candidates.

The manuscript can be obtained at:

PNAS link: http://www.pnas.org/content/early/2017/01/11/1616408114.full.pdf

Additional recent Adimab publications:

“Rapid assessment of oxidation via middle-down LCMS correlates with methionine side-chain solvent-accessible surface area for 121 clinical stage monoclonal antibodies.” Yang, R., Jain, T., Xu, Y., et al. mAbs (2017).

“Rapid profiling of RSV antibody repertoires from the memory B cells of naturally infected adult donors.” Gilman, M., Castellanos, C.A., Walker, L.M., et al. Science Immunology (2016).

“Broad epitope coverage of a human in vitro antibody library.” Sivasubramanian, A., Abdiche, Y., et al. mAbs (2016).

“Isolation of potent neutralizing antibodies from a survivor of the 2014 Ebola virus outbreak.” Bornholdt, Z.A., Walker, L.M., et al. Science (2016).

"Addressing polyspecificity of antibodies selected from an in vitro yeast presentation system: a FACS-based, high-throughput selection and analytical tool." Xu, Y., Krauland, E., et al. PEDS (2013).

01.10.17
Adimab Provides Annual Update on 2016 Partnerships and Milestones

Lebanon, New Hampshire – January 10, 2017 – Adimab, LLC, the global leader in the discovery and optimization of fully human monoclonal and bispecific antibodies, today announced that it has entered into definitive agreements with nine new companies in 2016. In addition, Adimab announced the expansion of seven of its current partnerships and the achievement of over 40 technical and development milestones across multiple existing collaborations.

Over the past eight years, Adimab has entered into over 40 partnerships for the discovery of therapeutic IgGs and bispecific antibodies, generating in excess of 150 therapeutic programs using the Adimab platform. The most advanced program is currently in Phase 2 clinical trials. New alliances for 2016 include collaborations with Takeda Pharmaceuticals, Iconic Therapeutics, Tizona Therapeutics, Scholar Rock, and iTeos Therapeutics, among others. In addition, Adimab expanded its partnerships with Innovent Biosciences and Jounce Therapeutics, and several others.

"We are focused on being a premier technology company, not a product company," commented Guy Van Meter, Vice President of Business Development at Adimab. "Our success is entirely dependent upon the success of our partners and, therefore, every program is very important to us. Speed is a critical aspect for many of our partners, but identifying a therapeutic lead that provides a competitive advantage is even more important."

"At Adimab, we are committed to continually improving and expanding our technical offering to provide the best antibody discovery platform in the industry," added Tillman Gerngross, Chief Executive Officer and Co-Founder of Adimab. "We want our partners to have solutions for all of their therapeutic approaches so that Adimab is the partner of choice in turning their biological insights into transformative drugs."

Adimab also announced that it achieved over 40 technical and development milestones in 2016 with Merck, Kyowa Hakko Kirin, Kite Pharma, Surface Oncology, GSK, and several others. Adimab partners exercised a total of 13 commercial licenses in 2016, in addition to Mersana and Innovent filing INDs and Arsanis advancing its lead program into Phase 2 clinical trials.

"Adimab was able to rapidly identify and screen a large number of antibodies that interact with HER2 in unique ways; this allowed us to select a lead antibody with superior ADC properties. XMT1522, our lead program, is comprised of this antibody conjugated to our highly differentiated Dolaflexin ADC platform, and has shown superior efficacy and tolerability in a broad range of pre-clinical models," said Anna Protopapas, Chief Executive Officer of Mersana Therapeutics. "Phase 1 trials for XMT1522 are ongoing."

"We have pursued numerous programs with Adimab and have experienced excellent success. Our anti-PD1 program has initiated clinical trials in 2016, a mere two years after completing our campaign with Adimab," added Michael Yu, Chief Executive Officer at Innovent. "The speed of the Adimab technology has helped Innovent rapidly develop multiple products."

Adimab has established antibody discovery collaborations with many leading pharmaceutical companies, such as Merck, Novo Nordisk, Biogen, GSK, Roche, Novartis, Eli Lilly, Genentech, Celgene, Gilead, Kyowa Hakko Kirin, Takeda and Sanofi. In addition, Adimab has partnered with several smaller publicly traded companies, such as Acceleron, Merrimack Pharmaceuticals, Kite, Five Prime, as well as leading venture-backed companies including Jounce, Mersana, Alector, Arsanis, Surface Oncology, Potenza, Tizona, Tusk and several academic institutions such as Memorial Sloan Kettering and MD Anderson. The Adimab antibody discovery and optimization platform has also been internalized by several larger pharma partners; Adi-inside partners include Merck, Novo Nordisk, Biogen and GSK.

12.09.16
Adimab Scientists Report the Isolation of Highly Potent anti-RSV Antibodies

Lebanon, New Hampshire – December 9, 2016 – Scientists at Adimab, LLC, the global leader in the discovery of human antibodies, today published a report in Science Immunology about the isolation of a panel of novel, highly potent anti-RSV antibodies from human donors. All antibodies were isolated from naturally infected adults using Adimab’s single B cell isolation technology. The newly reported panel comprises the most potent anti-RSV antibodies found in the literature to date. The work follows a publication from earlier this year on broadly neutralizing anti-Ebola antibodies generated using the same technology.

“We developed a fast and efficient B cell cloning technology that works seamlessly with our yeast-based antibody discovery and optimization platform,” Dr. Laura Walker, lead scientist of the study, remarked about the underlying technology that led to the isolation of this novel panel of antibodies. “We are excited about these antibodies for potential therapeutic use, and also about the contributions that the work stands to make to future vaccine design.”

Dr. Walker’s team cloned over 300 RSV-specific antibodies from the memory B cells of three healthy adult donors using the Adimab B cell isolation platform. With these antibodies, the authors were able to generate a comprehensive map of the antigenic topology of the RSV fusion (F) protein. The target protein exists in two conformations, known as prefusion and postfusion, the former of which has recently been stabilized by Dr. Jason McClellan’s lab at Dartmouth College. The team at Adimab was able to identify a previously undefined antigenic site on prefusion F, termed site V, which nearly half of the most potent neutralizing antibodies engaged.

“Working with Adimab has been great. It has given us the ability to identify antibodies from human donors with remarkable efficiency and speed,” said Dr. McLellan, Assistant Professor of Biochemistry at Dartmouth College’s Geisel School of Medicine. “With this new panel of antibodies in hand, we have created a detailed picture of the human antibody response to RSV infection. These results will facilitate the generation and validation of new RSV vaccine candidates.”

“Dr. Walker’s team has again shown the power of our human B cell isolation technology. Within weeks her team was able to isolate some of the most potently neutralizing anti-RSV antibodies reported to date. Naturally, we are excited about the prospect of improving the clinical outcomes of RSV infections and finding a suitable partner for clinical development and commercialization,” said Tillman Gerngross, Chief Executive Officer and Co-Founder of Adimab.

The study, entitled “Rapid profiling of RSV antibody repertoires from the memory B cells of naturally infected adult donors”, is available online and will be published in the December 9, 2016 issue of Science Immunology. This is the largest panel of RSV neutralizing antibodies published to date, and the sequences will be made available via GenBank.

Currently, Adimab’s B cell isolation technology can be deployed against any human or murine memory B cell source. This includes naturally infected or vaccinated donors, as well as immunized mice. The antibodies can be isolated, cloned, and produced for characterization in a matter of weeks. Once transferred into the Adimab system, the antibodies can be further optimized with a wide array of protein engineering tools. In the past year alone, Adimab has applied this technology to multiple targets including Ebola (published in Science in February 2016 and available here), RSV, CD3, and most recently to Zika virus.

06.07.16
Adimab and Innovent Expand Partnership for the Discovery of Antibodies and Bispecifics

Lebanon, New Hampshire and Suzhou, China – June 7, 2016 – Adimab, LLC , the global leader in the discovery and optimization of fully human monoclonal and bispecific antibodies, and Innovent Biologics, a premier biotechnology company in Suzhou, China, today announced a significant expansion of their existing collaboration. Over three years, Adimab will use its proprietary, yeast-based discovery platform to generate IgGs or bispecifics for development as therapeutic products for multiple targets chosen by Innovent. Innovent will retain worldwide commercial rights to these therapeutic products.

"We know from our previous projects that Adimab's reputation as the leading protein engineering company in the industry is well deserved. An antibody that came out of our relationship with Adimab is part of our recent partnership with Eli Lilly and Company," said Michael Yu, Chief Executive Officer and Co-Founder of Innovent. "Gaining broader access to Adimab was very important to achieving our long-term goals, so we are very pleased to have expanded our relationship."

"Innovent has been a great partner," said Tillman Gerngross, Chief Executive Officer and Co-Founder of Adimab. "They are quickly emerging as a substantial Asian biotech company and their leadership has demonstrated the ability to build an attractive pipeline across multiple disease areas. We are confident that with our protein engineering platform, Innovent will rapidly develop and move many more product candidates into clinical trials."

This most recent agreement further expands an earlier relationship that began in 2013.

Adimab’s funded discovery partners include many leading pharmaceutical companies, such as Merck, Novo Nordisk, Biogen, GSK, Roche, Novartis, Lilly, Genentech, Celgene, Gilead, Kyowa Hakko Kirin, Sanofi and others. Adimab has also partnered with many smaller companies, such as Merrimack Pharmaceuticals, Mersana, Five Prime and others, as well as academic institutions such as Memorial Sloan Kettering and MD Anderson. In addition, the Adimab antibody discovery and optimization platform and custom antibody libraries have been transferred to Merck, Novo Nordisk, Biogen and GSK for internal use.

04.27.16
Adimab Announces Two New Partnerships and Commercial Licenses with Lilly, Kite and Jounce

Lebanon, NH – April 27, 2016 – Adimab LLC, the global leader in the discovery and optimization of fully human monoclonal and bispecific antibodies, today announced independent partnerships with two new companies: iTeos Therapeutics and Kodiak Sciences. Under the terms of each agreement, Adimab will use its proprietary platform to discover and/or optimize antibodies against targets chosen by each company, who will have the right to develop and commercialize all therapeutics antibodies resulting from the collaboration.

"About three years ago we started partnering with early stage companies that were pursuing very innovative and novel disease biology," said Tillman Gerngross, Chief Executive Officer and Co-Founder of Adimab. "These partnerships have been quite successful. Our partners can immediately leverage our industry-leading discovery capabilities at a relative cost. This allows our partners to focus on the underlying biology for their programs and rapidly develop a pre-clinical pipeline."

"Adimab is clearly an excellent strategic fit for iTeos. The quality of Adimab's platform has consistently generated leads that are superior to the output from competing technologies," noted Christophe Quéva, Chief Scientific Officer of iTeos. "Also, the ease and speed with which we were able to come to business terms and finalize an agreement was a pleasant surprise. It allowed us to quickly move to the far more important part of the collaboration – generating high quality therapeutic candidates for our patients."

In addition, Adimab announced that Eli Lilly and Company, Kite Pharma and Jounce Therapeutics have all exercised independent commercial licenses to antibody programs generated under existing collaborations.

"We are pleased with the success of our collaboration with Adimab. The versatility and quality of the Adimab platform have been instrumental in supporting our CAR T cell therapies beyond KTE-C19," said Tony Polverino, Ph.D., Vice President, Research of Kite Pharma. "We look forward to continuing our partnership with Adimab to advance important therapies for cancer patients."

Over the past seven years, Adimab has established funded discovery collaborations with over 35 companies. Adimab's funded discovery partners include leading pharmaceutical companies, such as Novo Nordisk, Biogen, GSK, Roche, Novartis, Lilly, Genentech, Celgene, Gilead, Kyowa Hakko Kirin, Sanofi, Takeda and others. Adimab has also partnered with many mid-size and early-stage venture-backed companies, including Merrimack, Five Prime, Jounce, Innovent, Alector, Acceleron, Oncothyreon, Surface Oncology, Potenza, Arsanis and others, as well as academic institutions such as Memorial Sloan Kettering and MD Anderson. In addition to funded discovery programs, the Adimab antibody discovery and optimization platform and custom antibody libraries have been transferred to Merck, Novo Nordisk, Biogen, and GSK for internal use.

04.26.16
Adimab Announces Antibody Discovery Collaboration with Takeda

Lebanon, NH – April 26, 2016 – Adimab LLC, the global leader in the discovery and optimization of fully human monoclonal and bispecific antibodies, today announced a multi-target partnership with Takeda Pharmaceutical Company Ltd. Under the terms of the agreement, Adimab will use its proprietary platform to discover and optimize antibodies against multiple targets chosen by Takeda, who will have the right to develop and commercialize therapeutic programs resulting from the collaboration.

"We are pleased to be working with a company with such deep expertise in antibody discovery and engineering," stated Christopher Claiborne, Ph.D., Head of Oncology Discovery at Takeda. "Adimab's breadth of technical offerings, including bispecifics, as well as their reputation in the industry enables us to continue fulfilling our mission of aspiring to cure cancer."

"We are excited to have Takeda as a partner, and we look forward to demonstrating Adimab's advantages to the Takeda team," said Tillman Gerngross, Chief Executive Officer and Co-Founder of Adimab. "This partnership, like most of our initial partnerships, will focus on a handful of projects. Our goal is to have our partners see the output from the collaboration and fall in love with the platform. We are always happy to expand the initial collaboration into additional funded discovery projects, or even transfer the platform to our partner's facilities – to date most of our partnerships have expanded in some way."

Under the terms of the agreement, Adimab will use its proprietary yeast-based discovery and optimization platform or its proprietary rapid B cell sorting capabilities to identify fully human antibodies and against selected targets. For each target, Adimab will grant Takeda the right to research antibodies generated during the collaboration for potential use in therapeutic products. Adimab will receive an undisclosed upfront payment, research fees and technical milestones. In addition, for each target Takeda will have the option to exclusively license antibodies generated during the collaboration as a therapeutic lead, for which Adimab would receive license fees, clinical milestones and royalties on product sales.

Over the past seven years, Adimab has established funded discovery collaborations with over 35 companies. With this collaboration, Takeda joins Adimab's other large pharmaceutical funded discovery partners, including Novo Nordisk, Biogen, GSK, Roche, Novartis, Eli Lilly, Genentech, Celgene, Gilead, Kyowa Hakko Kirin, Sanofi and others. Adimab has also partnered with many mid-size and early-stage venture-backed companies, including Merrimack, Five Prime, Jounce, Innovent, Alector, Acceleron, Oncothyreon, Surface Oncology, Potenza, Arsanis and others, as well as academic institutions such as Memorial Sloan Kettering and MD Anderson. In addition to funded discovery programs, the Adimab antibody discovery and optimization platform and custom antibody libraries have been transferred to Merck, Novo Nordisk, Biogen and GSK for internal use.

04.25.16
Adimab Expands Bispecific Antibody Offering with Novel CD3 Program

Lebanon, NH – April 25, 2016 – Adimab, LLC, the global leader in the discovery and optimization of fully human monoclonal and bispecific antibodies, today announced that it has used its proprietary antibody discovery technology to generate multiple new anti-CD3 binders which are available for out-licensing. Adimab also announced that it has expanded its collaboration with two current partners to include access to these novel anti-CD3 binders.

Adimab's CD3 program consists of a panel of fully human antibodies against CD3; the binders were originally discovered using Adimab's proprietary B cell isolation process and then significantly enhanced using Adimab’s optimization capabilities. Adimab will be licensing these anti-CD3 binders on a non-exclusive basis for use in bispecific antibodies, with binding partners coming either from Adimab or its licensees.

Under the terms of the aforementioned agreements, each partner has the ability to incorporate Adimab's anti-CD3 binders into their own therapeutic bispecific molecules, or have Adimab design anti-CD3-based bispecifics for them.

"Our novel CD3 program expands the range of solutions we can offer to our partners," said Guy Van Meter, Vice President of Business Development of Adimab. "Bispecific therapeutics are a very important aspect of our business and our new CD3 program, as well as our common light chain capabilities, have been of significant interest to many of our partners."

"Adimab continues to evolve and improve the platform, with the goal to be the industry's premier independent technology provider in the antibody discovery space for the next decade. Adimab is not pursuing an internal product pipeline, and therefore focuses significant effort on technology development and improvements," said Tillman Gerngross, Chief Executive Officer and Co-Founder of Adimab. "Adimab's new B cell isolation process combined with the Adimab optimization capabilities can be applied to very challenging targets and still allow for dramatic enhancements to potential leads. This new approach will enable the generation of therapeutic programs for a broader range of targets."

Over the past seven years, Adimab has established funded discovery collaborations with over 35 companies. Adimab’s funded discovery partners include Novo Nordisk, Biogen, GSK, Roche, Novartis, Eli Lilly, Genentech, Celgene, Gilead, Kyowa Hakko Kirin, Sanofi and others. Adimab has also partnered with many mid-size and early-stage venture-backed companies, including Merrimack, Five Prime, Jounce, Innovent, Alector, Acceleron, Oncothyreon, Surface Oncology, Potenza, Arsanis and others, as well as academic institutions such as Memorial Sloan Kettering and MD Anderson. In addition to funded discovery programs, the Adimab antibody discovery and optimization platform and custom antibody libraries have been transferred to Merck, Novo Nordisk, Biogen, and GSK for internal use.

02.18.16
Adimab Scientists Report the Isolation of Highly Potent Anti-Ebola Virus Antibodies from Recent Zaire Outbreak

Lebanon, NH – February 18, 2016 – Adimab, LLC, a global leader in the discovery of human antibodies, today reported the isolation of a broad panel of neutralizing anti-Ebola virus antibodies from a survivor of the recent Zaire outbreak. The work, published online today in the journal Science, highlights the remarkable speed of Adimab's recently launched single B cell isolation platform, and constitutes the largest panel of functional anti-Ebola antibodies reported in the scientific literature to date. The sequences of all antibodies isolated in this study will be made freely available to the research community through the GenBank database.

"Our Science paper describes the first in-depth view into the human antibody response to Ebola virus," said Laura Walker, Ph.D., Senior Scientist at Adimab, and the corresponding author of the study. "Within weeks of receiving a blood sample from a survivor of the 2014 Ebola outbreak, we were able to isolate and characterize over 300 monoclonal antibodies that reacted with the Ebola virus surface glycoprotein."

After the initial isolation and characterization of the anti-Ebola antibodies at Adimab, several leading institutions in the field of virology, including The Scripps Research Institute, La Jolla, CA and the US Army Medical Research Institute of Infectious Diseases (USAMRIID), Fort Detrick, MD, provided an in-depth analysis of the therapeutic potential of these newly isolated antibodies. "Over the past decade, our laboratory has analyzed over one hundred antibodies against the Ebola virus," commented Pamela Glass, Ph.D., Senior Investigator at USAMRIID. "Several of the antibodies provided by Dr. Walker's team display the most potent neutralization and protection we have ever seen."

Additional structural analysis at The Scripps Research Institute provided further insight into the diversity of the human immune response to Ebola. "The antibody panel discovered by Adimab covers every previously known binding site on Ebola virus and their work further revealed a new, highly potent neutralizing site, that has not been reported to date," said Prof. Andrew Ward, Scripps Research Institute, a co-author of the study.

"In less than two months the Adimab team isolated more neutralizing Ebola antibodies than the entire Ebola field has reported in the past two decades," noted Tillman Gerngross, Ph.D., CEO and Co-Founder of Adimab and a Professor of Bioengineering at Dartmouth College. "The global public health community has been looking for a rapid response platform to emerging infectious disease threats and Laura's team has set an entirely new standard for rapidly isolating protective antibodies that could be turned into effective therapeutics. We now have a broadly applicable platform to deal with these threats."

"Not only has the Adimab team isolated an extensive panel of therapeutically promising Ebola antibodies in such a short time frame, but the fact that they have made these antibodies available to the research community for further studies is remarkable and shows their humanitarian intent to advance the field without regard for commercial gain," said John Dye, Ph.D., Chief of Viral Immunology at USAMRIID.

Adimab separately noted that it has applied its B cell isolation platform against the respiratory syncytial virus (RSV) with similar results. The Company also intends to demonstrate the applicability of the B cell isolation platform against the Zika virus.

The study, entitled "Isolation of Potent Neutralizing Antibodies from a Survivor of the 2014 Ebola Virus Outbreak", is available online and will be published in the February 18th, 2016 issue of Science. The sequences generated in this work will be made available to the research community via GenBank.

01.12.16
Adimab Announces Technology Transfer Agreement with Merck

Lebanon, New Hampshire – January 12, 2016 – Adimab, LLC, the global leader in the discovery and optimization of fully human monoclonal and bispecific antibodies, today announced that it has entered into a definitive agreement with Merck, known as MSD outside the United States and Canada, to transfer Adimab’s antibody technology to Merck Research Laboratories for the discovery and optimization of monoclonal and bispecific therapeutic antibody candidates. This technology transfer expands an ongoing collaboration between the two companies, initiated in 2009, which has yielded several undisclosed therapeutic candidates for Merck.

"We are very pleased that Merck will internalize the Adimab technology and apply it more broadly across its R&D programs," said Tillman Gerngross, Chief Executive Officer and Co-Founder of Adimab. "Adimab is focused on providing the industry with the best antibody discovery and protein engineering platform. To date, we have entered into over 35 partnerships across the biopharmaceutical industry focused on naïve IgG discovery, optimization, bispecifics, rapid B-cell cloning, and other protein engineering applications. The majority of these partners have expanded after seeing results from their initial programs. Adimab continues to make significant investments in the platform to ensure that our partners have access to the most advanced protein engineering tools in the industry."

"Merck’s long-standing relationship with Adimab has provided important insights into the application of the technology and how it can complement our growing biologics discovery and development capabilities," said Yuan Xu, Senior Vice President Biologics and Vaccines, Merck Research Laboratories. "Transferring the Adimab platform into our own labs will allow us to apply the technology and custom human antibody libraries to support our pipeline of therapeutic biologic candidates."

Under the terms of the agreement, Adimab will transfer and license its proprietary antibody discovery and optimization platform to Merck, enabling broad use by Merck researchers of the Adimab technology. Merck will receive a custom human antibody library that is unique and exclusive to Merck, and will obtain a license to the Adimab platform for use in all therapeutic areas and all targets. Merck has also secured an option to receive continued improvements to the Adimab platform, including access to new antibody libraries. Adimab will receive an undisclosed upfront signing fee, future payments upon achievement of specified preclinical and clinical milestones, and royalties on any therapeutic products resulting from use of the technology.

Over the past six years, Adimab has established funded discovery collaborations with over 35 companies, including Merck who was one of the first Adimab partners. Other funded discovery partners include leading pharmaceutical companies, such as Novo Nordisk, Biogen, GSK, Roche, Novartis, Eli Lilly, Genentech, Celgene, Gilead, Kyowa Hakko Kirin, Sanofi and others. Adimab has also partnered with many mid-size and early-stage venture-backed companies, including Merrimack, Five Prime, Jounce, Innovent, Alector, Acceleron, Oncothyreon, Surface Oncology, Potenza, Arsanis and others. In addition to Merck, the Adimab antibody discovery and optimization platform and custom antibody libraries have been transferred to Novo Nordisk, Biogen and GSK for internal use.

01.11.16
Adimab Provides Update on Recent Partnerships and Milestones

Lebanon, NH – January 11, 2016 – Adimab, LLC, the global leader in the discovery and optimization of fully human monoclonal and bispecific antibodies, today announced that it has entered into definitive agreements with several new companies, as well as expanded partnerships with several of its current partners. In addition, Adimab announced the achievement of technical and development milestones under a number of existing agreements.

In less than seven years, Adimab has entered into over 35 partnerships focused on the discovery of therapeutic IgGs and bispecific antibodies. Adimab’s partnering strategy initially focused on large pharmaceutical companies. However, more recently the company has been able to craft deal structures to accommodate the strategic needs of many innovative early-stage companies backed by leading venture firms like Third Rock Ventures, Atlas Ventures, MPM, Polaris Partners and Orbimed Advisors. Recent new partners include Fortress Biotech, Torque Therapeutics, Tizona Therapeutics, and Tusk Therapeutics.

"In addition to welcoming new partners, we take tremendous pride in generating longer-term relationships with our existing partners," commented Guy Van Meter, Vice President of Business Development at Adimab. "Most of Adimab's existing partners have sought to expand their relationships beyond the initial terms of the engagement; recently expanded partnerships include those with Five Prime, Innovent Biologics, Acceleron, Potenza, Jounce Therapeutics, Surface Oncology, and Alector."

"Adimab's discovery and protein engineering capabilities surpass simple affinity maturation, and can be utilized to enhance multiple attributes of an antibody or bi-specific to ensure the best possible product candidates for a given therapeutic program," added Tillman Gerngross, Chief Executive Officer and Co-Founder of Adimab. "We are very pleased to see so many of our existing collaborations expanding into broader partnerships. The more successful our projects are, the more our partners want to do – it's as simple as that."

Adimab also announced that it has recently achieved technical milestones with several partners, including Merck, Acceleron Pharmaceuticals, Kite Pharma, Surface Oncology, and Potenza Therapeutics. Merck has recently exercised a commercial license under one of its earlier agreements and Arsanis Biosciences has initiated a Phase I clinical study in healthy volunteers.

"Adimab's protein engineering capabilities generated therapeutic leads for our ASN100 program that no other technology could have produced – including a very unique antibody that is highly effective against five separate toxins of Staphylococcus aureus with very low sequence homology," said Eszter Nagy, Chief Scientific Officer and Co-Founder of Arsanis. "We are very happy to have a partnership with Adimab and are pleased that our first program has already reached the clinic."

Adimab’s funded discovery partners include many leading pharmaceutical companies, such as Novo Nordisk, Biogen, GSK, Roche, Novartis, Eli Lilly, Genentech, Celgene, Gilead, Kyowa Hakko Kirin, Sanofi and others. Adimab has also partnered with many smaller companies, such as Merrimack Pharmaceuticals, Mersana, Five Prime and others, as well as academic institutions such as Memorial Sloan Kettering and MD Anderson. In addition, the Adimab antibody discovery and optimization platform and custom antibody libraries have been transferred to Novo Nordisk, Biogen, and GSK for internal use.

12.08.15
Adimab Establishes Antibody Discovery Collaborations with MD Anderson and Memorial Sloan Kettering

Lebanon, NH – December 8, 2015 – Adimab, LLC, the global leader in the discovery and optimization of fully human monoclonal and bispecific antibodies, today announced two independent academic collaborations, one with The University of Texas MD Anderson Cancer Center and the other with Memorial Sloan Kettering. In each of these collaborations, Adimab will use its proprietary yeast-based discovery platform to generate IgGs for development as therapeutic products. MD Anderson and Memorial Sloan Kettering retain full commercial rights to therapeutic products generated in their respective projects. Adimab will also use its recently launched rapid B-cell sorting capabilities in one or more of the programs.

"We recognize that leading academic centers like MD Anderson and Memorial Sloan Kettering are increasingly playing a role beyond elucidating novel target biology," said Tillman Gerngross, Chief Executive Officer and Co-Founder of Adimab. "These new collaborations are indicative of how we will structure future partnerships with academic and non-profit organizations – helping leading investigators at top academic institutions generate more downstream value from publicly funded research. These partnerships are ideal for fast-tracking high-quality, early-stage research into clinical trials."

"Over the years, MSK investigators have discovered novel therapeutic targets for various cancer types. By leveraging Adimab's capabilities in antibody generation and development, we expect to generate panels of high-quality antibodies against these targets that MSK can then assess in functional studies and identify clinical candidates for further development," said Dr. Alexander Rudensky from Memorial Sloan Kettering. "Our goal is to generate therapeutic antibodies against novel targets to improve outcomes and positively impact patient care, in keeping with MSK's mission."

"MD Anderson has broad expertise and insight around novel target biology, but also the established infrastructure and expertise to bring novel therapies directly to patients," stated Michael A. Curran, Ph.D., Assistant Professor of Immunology at MD Anderson. "Getting advanced therapeutic approaches to patients quickly is the goal. High-quality therapeutic leads with differentiating biology are critical for this approach."

Under the terms of these two agreements, Adimab will use its proprietary yeast-based discovery and optimization platform, at times combined with its proprietary rapid B-cell sorting capabilities, to identify fully human antibodies against selected targets. For each target, Adimab will grant its partners the right to research antibodies generated during the collaboration for potential use in therapeutic products. For both collaborations, Adimab will receive undisclosed research fees to fund all discovery work, as well as downstream economics associated with license fees, milestones and royalties. The academic partner will retain all commercial rights and hold responsibility for the ongoing commercialization of the programs.

Over the past six years, Adimab has established funded discovery collaborations with over 35 companies. Adimab's funded discovery partners include many leading pharmaceutical companies, such as Merck, Roche, Novartis, Eli Lilly, Genentech, Gilead, Celgene, Kyowa Hakko Kirin, Sanofi and others. Adimab has also partnered with many mid-size and early stage venture-backed companies, including Merrimack, Five Prime, Jounce, Innovent, Alector, Acceleron, Oncothyreon, Surface Oncology, Potenza, Arsanis and others. In addition, Adimab has transferred its platform for broad use to GSK, Biogen and Novo Nordisk.

06.15.15
Adimab Establishes New Collaboration with Kite Pharma for the Discovery of Antibodies for T-cell Therapies

Lebanon, NH – June 16, 2015 – Adimab, LLC, the technology leader in the discovery of fully human antibodies and bispecifics, today announced a new collaboration with Kite Pharma, Inc., (Nasdaq:KITE). Under the terms of the agreement, Adimab will use its proprietary platform to generate IgGs against multiple targets selected by Kite.

"Kite has established itself as a leader in the field of engineered autologous cell therapies, and we are excited to have the opportunity to work with them," said Tillman Gerngross, Chief Executive Officer and co-founder of Adimab. "Our platform can rapidly deliver a diverse panel of antibodies with varying affinities and ultra-high selectivity."

"Kite is focused on finding partnerships, such as this collaboration with Adimab, that help us establish a competitive advantage in the CAR-T space," said Margo Roberts, Ph.D., Chief Scientific Officer of Kite.

Kite and Adimab have entered into a collaboration whereby Adimab will use its proprietary discovery and optimization platform to identify fully human antibodies against selected targets. For each target, the agreement grants Kite the right to research antibodies generated during the collaboration for potential use in therapeutic CAR-T products. Kite will also have the option to exclusively license antibodies for development and commercialization as therapeutic CAR products. Adimab will receive an undisclosed upfront payment, research fees and technical milestones, as well as license fees, certain additional milestones and royalties on any therapeutic CAR product sales that are optioned under the agreement.

Over the past 5+ years, Adimab has established funded discovery collaborations with over 30 companies. Adimab’s funded discovery partners include many leading pharmaceutical companies, such as Merck, Roche, Novartis, Eli Lilly, Genentech, Gilead, Kyowa Hakko Kirin, Sanofi and others. Adimab has also partnered with many mid-size and early-stage venture-backed companies, including Merrimack, Five Prime, Jounce, Innovent, Alector, Acceleron, Oncothyreon, Surface Oncology, Potenza, Arsanis and others. In addition, Adimab has transferred its platform for broad use to GSK, Biogen and Novo Nordisk.

05.07.15
Adimab Establishes New Partnership with Celgene for Discovery of Antibodies and Bispecifics for Next-Generation Therapeutics for Patients

Lebanon, NH – May 7, 2015 – Adimab, LLC, the technology leader in the discovery of fully human antibodies, today announced a new collaboration with Celgene, which follows an earlier 2013 agreement between the two parties. Under the terms of the new agreement, Adimab may generate novel common light chain (cLC) libraries with Celgene and use its proprietary platform to generate IgGs against multiple targets. Celgene will have the right to develop and commercialize therapeutic antibodies resulting from the collaboration.

"We are very pleased that Celgene has chosen to enter into a new discovery collaboration with Adimab," said Tillman Gerngross, Chief Executive Officer and co-founder of Adimab. "We have over 30 partnerships, and almost every partner has either expanded their relationship or is in discussions to expand. Our ongoing partnering success is based on a few key elements: our industry-leading capabilities in antibody discovery, the consistency by which we deliver successful therapeutic programs, and our ability to create very productive relationships with our partner's research teams."

"We had high expectations for the initial collaboration, and are very pleased with its progress. We have also been impressed with Adimab's ongoing technical development efforts, in particular Adimab's ability to build highly diverse antibody libraries based on single common light chains," said Ho Cho, Vice President of Celgene Biotherapeutics. "Celgene expects to develop a robust antibody-based clinical pipeline and we rely on innovative companies, such as Adimab, to make this happen."

Under the terms of the new agreement Adimab may build novel common light chain libraries with Celgene. Adimab may use these common light chain libraries for the discovery and optimization of fully human antibodies against multiple targets. For each project, the agreement grants Celgene the right to research antibodies generated during the collaboration. Celgene will also have an option to exclusively license antibodies for development and commercialization. The initial term of the partnership is for two years, with an option to extend for an additional two years. Adimab will receive an undisclosed upfront payment, as well as license fees, clinical milestones and royalties on any product that is optioned under the agreement.

"Adimab is clearly becoming a leader in the generation of bispecific antibodies. Our partners value our ability to enhance almost any bispecific construct and Adimab's common light chain libraries allow us to generate fully-human IgG-like bispecifics against any two targets, whether a partner already has an antibody with a given light chain or we discover the antibody de novo. Our cLC libraries exceed 10^10 in diversity, and enable the rapid discovery of highly specific and developable leads," said Guy Van Meter, Vice President of Business Development at Adimab. "Every year we invest significantly in technology development to ensure that our discovery and optimization capabilities are second to none."

Over the past 5+ years, Adimab has established funded discovery collaborations with over 30 companies. Adimab's funded discovery partners include many leading pharmaceutical companies, such as Merck, Roche, Novartis, Eli Lilly, Genentech, Gilead, Kyowa Hakko Kirin, Sanofi and others. Adimab has also partnered with many mid-size and early stage venture backed companies, including Merrimack, Five Prime, Jounce, Innovent, Alector, Acceleron, Oncothyreon, Surface Oncology, Potenza, Arsanis and others. In addition, Adimab has transferred its platform for broad use to GSK, Biogen and Novo Nordisk.

02.05.15
Adimab Announces New Bispecific Antibody Collaboration with Sanofi

Lebanon, NH – February 6, 2015 – Adimab, LLC, the technology leader in the discovery of fully human antibodies and bispecifics, today announced a multi-target discovery and optimization collaboration with Sanofi. Under the terms of the Agreement, Adimab will use its proprietary platform to generate bispecific molecules against multiple targets. Sanofi will have the right to develop and commercialize all therapeutic antibodies and bispecifics resulting from the collaboration.

"We are very pleased to have another major pharma partner in Sanofi," said Tillman Gerngross, CEO and co-founder of Adimab. “Adimab has recently emerged as a major player in the bispecifics discovery space. Our unique protein engineering capabilities allow us to rapidly build libraries around almost any bispecific construct. All leads are ‘filtered’ through Adimab’s genetically modified yeast strain leading to well-expressing and stable therapeutic leads that can readily be assessed for biological function. No other technology can create such a diverse panel of functional and developable leads in such a short time," he added.

Adimab and Sanofi have entered into a collaboration whereby Adimab will use its proprietary discovery and optimization platform to identify fully human antibodies or bispecifics against multiple targets. For each project, the agreement grants Sanofi the right to research antibodies and bispecifics generated during the collaboration for potential use as therapeutic products. Under the terms of the Agreement, Adimab will receive an undisclosed upfront payment, research fees and technical milestones. In addition, for each target, Sanofi will have the option to exclusively license antibodies and bispecifics generated during the collaboration. If Sanofi exercises its option for a particular therapeutic lead, Adimab would receive license fees, clinical milestones and royalties on product sales.

“More and more companies are focused on bispecific approaches to go after intricate disease biology,” said Guy Van Meter, Vice President of Business Development at Adimab. “We have made substantial investments to develop our bispecific platform over the past three years. Our capabilities have grown tremendously, and Adimab has added 18 new bispecific therapeutic programs in the past 12 months alone.”

Over the past five years, Adimab has established funded discovery collaborations with over 30 companies. Adimab’s funded discovery partners include many leading pharmaceutical companies, such as Merck, Roche, Novartis, Eli Lilly, Genentech, Gilead, Kyowa Hakko Kirin, Celgene and Sanofi. Adimab has strategically partnered with many other companies as well, including Merrimack, Five Prime, Jounce, Innovent, Alector, Acceleron, Oncothyreon, Surface Oncology, Potenza and Arsanis. In addition, Adimab has transferred its platform for broad use to GSK, Biogen Idec and Novo Nordisk.

01.10.15
Adimab Announces Expansion of its Collaboration with GSK for the Discovery of Bispecific Antibodies

Lebanon, NH – January 12, 2015 – Adimab, LLC, a technology leader in the discovery of fully human antibodies and bispecifics, today announced that GlaxoSmithKline (GSK) has broadened its relationship with Adimab. Under an expanded collaboration, Adimab will build a unique custom library for GSK for use in generating bispecific antibody leads. Adimab will use that library as well as existing Adimab technology in collaboration with GSK to discover antibodies against multiple targets and generate bispecific antibodies against combinations of those targets. Adimab will also transfer the novel library to GSK for its internal use in the discovery of bispecifics. GSK will have the right to develop and commercialize therapeutic bispecifics generated from the library. Today’s announcement expands on Adimab’s first platform technology transfer and license agreement, which was entered into with GSK in 2013.

“We are excited that GSK has decided to be the first company to take advantage of Adimab’s unique ability to generate focused antibody libraries for our partners,” said Tillman Gerngross, CEO and co-founder of Adimab. “The Adimab platform can identify highly specialized functional IgGs, and incorporate them rapidly into stable, well-expressing bispecific leads. Further, the Adimab platform is a protein engineering tool that allows us to optimize molecules in virtually any bispecific format.”

“GSK has an interest in rapidly assessing biology from bispecific molecules with various target combinations, and the Adimab platform fully provides us with the quality and speed we need,” said Neil Brewis, Head of Biopharmaceutical Research at GSK. “Our existing collaboration has been highly productive, and this expansion reflects our appreciation of Adimab’s capabilities and collaborative approach.”

Over the past five years, Adimab has established funded discovery collaborations with more than 25 companies. Adimab’s funded discovery partners include many leading pharmaceutical companies, such as Merck, Roche, Novartis, Eli Lilly, Genentech, Gilead, Kyowa Hakko Kirin and Celgene. Adimab has strategically partnered with many other companies as well, including Merrimack, Five Prime, Jounce, Innovent, Alector and Arsanis. In addition, Adimab has transferred its platform for broad use to GSK, Biogen Idec and Novo Nordisk.

01.09.15
Adimab Announces New Partnerships with Acceleron, Oncothyreon, Surface Oncology and Potenza

Lebanon, NH – January 9, 2015 – Adimab, LLC, the technology leader in the discovery of monoclonal and bispecific antibodies, today announced independent discovery collaborations with Acceleron Pharma, Inc., Oncothyreon, Inc., Surface Oncology, Inc. and Potenza Therapeutics, Inc. All four collaborations are structured as funded discovery programs in which Adimab will discover and optimize therapeutic monoclonal or bispecific antibodies against multiple targets for each partner.

“These new partnerships epitomize the growing trend of highly innovative discovery programs originating in smaller and mid-sized biotech companies,” said Tillman Gerngross, Chief Executive Officer and co-founder of Adimab. “The Adimab platform is the optimal tool to probe and elucidate complex biology, and we look forward to deploying our capabilities towards the unique problems our partners are working on.”

Adimab’s New Partners Share Their Enthusiasm

“Acceleron has designed, manufactured, and developed several receptor fusion proteins and as we continue to expand our pipeline, we believe having access to a world-class platform to rapidly generate antibodies will be a valuable addition to our discovery efforts,” said John Knopf, Chief Executive Officer at Acceleron. “After surveying the antibody technology landscape, we concluded that Adimab is the best option for us and we look forward to a successful partnership.”

“Our partnership with Adimab is enabling Surface Oncology to meet its strategic goals,” stated Scott Chappel, Chief Technology Officer at Surface Oncology. “Adimab’s technology is rapidly delivering an impressive breadth and quality of antibodies.”

“We are focused on rapidly advancing therapeutic antibodies toward the clinic, and the Adimab technology is key to helping us achieve this goal,” said Dan Hicklin, Ph.D., President and Chief Executive Officer at Potenza. “Adimab delivered antibodies to us within two months of starting the first project.”

Under the terms of each of these four agreements, Adimab will use its proprietary discovery and optimization platform to identify fully human antibodies or bispecifics for its partners. These agreements generally grant Adimab’s partners the right to develop and commercialize antibodies and, in some instances, bispecifics generated during the collaboration for potential use as therapeutic products. Adimab’s partners will typically fund research at Adimab and have the option to exclusively license antibodies and bispecifics generated during the collaboration. While the terms of individual agreements may vary, if a partner exercises its option for a particular target, Adimab will usually receive license fees, clinical milestones and royalties on therapeutic product sales.

New Milestones Achieved by Current Partners

Genentech has exercised a commercial license to antibodies identified by Adimab to an undisclosed target. Genentech has exclusive development and commercialization rights to such antibodies.

In addition, Adimab announced the achievement of technical milestones from its ongoing collaborations with Merck & Co., Innovent, Acceleron, Surface Oncology and Potenza.

Over the past five years, Adimab has established funded discovery collaborations with over 25 companies. These funded discovery partners include many leading pharmaceutical companies, such as Merck, Roche, Novartis, Eli Lilly, Genentech, Gilead, Kyowa Hakko Kirin and Celgene. Adimab has strategically partnered with many other companies as well, including Merrimack, Five Prime, Jounce, Innovent, Alector and Arsanis. In addition, Adimab has transferred its platform for broad use to GSK, Biogen Idec and Novo Nordisk.

06.20.14
Adimab Announces 50th Therapeutic Program Under Its Funded Discovery Partnerships

Lebanon, NH – June 20, 2014 – Adimab, LLC, a leader in the discovery and optimization of monoclonal and bispecific antibodies, today announced the 50th therapeutic program under its funded discovery partnerships. Adimab launched its antibody discovery and optimization platform in the middle of 2009 and in less than five years has formed collaborations with more than 20 partners encompassing 50 therapeutic programs. In addition, Adimab announced today that new commercial licenses have been exercised from the funded discovery partnerships with Arsanis Biosciences, Merrimack Pharmaceuticals and Mersana Therapeutics.

Funded Discovery Partnerships

Under Adimab's funded discovery partnerships, Adimab applies its proprietary platform to generate therapeutic antibodies against any target of a partner’s interest. Adimab’s funded discovery partners include top pharmaceutical companies such as Merck, Roche, Novartis, Eli Lilly, Genentech, Biogen Idec, Novo Nordisk, Gilead, Kyowa Hakko Kirin, Pfizer, Celgene and innovative biotechnology companies such as Arsanis, Jounce, Five Prime Therapeutics, Alector, Mersana, and others. Adimab typically receives various upfront payments, commercial license fees, development milestones, and downstream milestones and royalties on product sales.

“Adimab's antibody discovery and optimization platform is remarkable. This has been a highly successful partnership for Arsanis,” commented Eszter Nagy, President, CSO and co-founder of Arsanis Biosciences. “Our therapeutic program was technically quite challenging and aimed for antibodies binding to several target molecules that share limited homology, but Adimab's protein engineering capabilities enabled us to generate exceptional lead candidates.”

“The epitope coverage generated by Adimab's platform is absolutely impressive,” said Donald A. Bergstrom, MD, PhD, CMO of Mersana. “In our collaborative efforts on multiple targets, Adimab's technology identified a never-before reported epitope, and provided us with multiple, diverse lead antibodies for our pre-clinical program. We have selected an antibody for our target of interest which is an ideal fit with Mersana's strategy of highly customized, next generation ADCs.”

Adimab's novel and proprietary yeast-based platform has significant advantages over traditional antibody discovery approaches, such as phage display, yeast display, and in vivo approaches. The Adimab yeast has been extensively engineered with over 20 genetic modifications, which allow for large and diverse libraries, efficient transport of developable, whole IgGs and large bispecific molecules through the secretory pathway, and presentation on the cell surface. Adimab rapidly generates panels of leads across all possible epitopes and initial functional leads can undergo protein engineering to create the highest quality therapeutic programs.

In light of achieving this milestone, Tillman Gerngross, CEO and co-founder of Adimab, observed, “Our industry is evolving, and companies are clearly seeking advantages for their programs at the discovery stage in order to be competitive and justify the significant expenses associated with drug development. In addition, targets are getting more challenging, and therapeutic molecules are getting more complex. Rapid protein engineering is the solution.”

“We believe that partnerships with Adimab continue to be in high demand because our collaborators value the versatility and speed of our platform. Our partners are able to precisely define the quality and characteristics of their antibodies – or bispecifics – and our highly efficient protein engineering capabilities yield the desired candidates to provide them with a competitive advantage over others in the industry,” added Guy Van Meter, Adimab's Head of Business Development.

New Commercial Licenses

Several of Adimab's funded discovery partners have exercised options to obtain commercial licenses for the antibodies generated under Adimab's Funded Discovery Program.

• Arsanis Biosciences has exercised a commercial license to antibodies identified by Adimab to multiple undisclosed targets. Arsanis has exclusive development and commercialization rights to such antibodies. This is the second commercial license exercised by Arsanis.

• Merrimack Pharmaceuticals has exercised a commercial license to antibodies identified by Adimab to an undisclosed target. Merrimack has exclusive development and commercialization rights to such antibodies.This is the second commercial license exercised by Merrimack.

• In addition, Mersana Therapeutics has exercised a commercial license to antibodies identified by Adimab to an undisclosed target. Mersana has exclusive development and commercialization rights to such antibodies.This is the first commercial license exercised by Mersana.

01.09.14
Adimab Announces New Partnerships with Jounce, Five Prime, and Alector

Lebanon, NH – January 9, 2014 – Adimab, LLC, a leader in the discovery of monoclonal and bispecific antibodies, today announced collaborations with Jounce, Inc., Five Prime Therapeutics, Inc., and Alector, LLC. All three collaborations are structured as funded discovery deals whereby each partner may provide multiple targets to Adimab for the discovery and optimization of therapeutic monoclonal or bispecific antibodies.

“Adimab is focused on partnering with the best drug developers in the world, whether they are major pharmaceutical companies or smaller biotech companies,” said Tillman Gerngross, Co-Founder and Chief Executive Officer of Adimab. “We try to be flexible in structuring partnerships to ensure that we can work with the smartest and most experienced teams that are well positioned to take advantage of Adimab’s unique capabilities. Jounce, Five Prime, and Alector are good examples of that.”

This enthusiasm is echoed by Adimab’s newest partners.

“We view Adimab as a leader in the field in antibody discovery and having access to their technology will enhance Jounce’s ability to rapidly advance the discovery and development of novel therapeutics,” said Cary Pfeffer, Interim Chief Executive Officer of Jounce. “Adimab’s flexibility in structuring the transaction allowed us to take advantage of their world-class technology under terms that work well for a company of our size.”

“Five Prime is using its proprietary platform to discover proteins that potentially regulate the immune system and these molecules can be targets for therapeutic antibodies,” said Lewis T. "Rusty" Williams, M.D., Ph.D., President and Chief Executive Officer of Five Prime. “Adimab’s technology platform provides a rapid and effective means to generate therapeutic antibodies, allowing us to accelerate our research and development.”

“Adimab has demonstrated that its antibody discovery and optimization platform has significant advantages over alternative approaches,” said Arnon Rosenthal, Co-Founder, CEO and President of Alector. “We are thrilled to be leveraging the speed and flexibility of the Adimab platform against our targets and were excited to find terms that work for a company of our size.”

Under the terms of each of these three agreements, Adimab will use its proprietary discovery and optimization platform to identify fully human antibodies or bispecifics for its customers. These agreements generally grant Adimab’s partners the right to develop and commercialize antibodies and, in some instances, bispecifics generated during the collaboration for potential use as therapeutic products. Adimab’s partners will typically fund research at Adimab and have the option to exclusively license antibodies and bispecifics generated during the collaboration. While the terms of individual agreements may vary, if a partner exercises its option for a particular target, Adimab would usually receive license fees, clinical milestones and royalties on therapeutic product sales.

Over the past four years, Adimab has established numerous partnerships with leading pharmaceutical companies, including Merck, Roche, Novartis, Eli Lilly, Genentech, Biogen Idec, Novo Nordisk, Human Genome Sciences, Gilead, Kyowa Hakka Kirin, GSK, and Celgene. Adimab's partnerships range from single-target funded discovery projects to larger, multi-target funded discovery collaborations. In 2013, Adimab rolled out its technology transfer program, which allows pharmaceutical companies to obtain Adimab’s antibody discovery platform and custom antibody libraries for internal use at the Partner’s research site. Early adopters of Adimab’s technology transfer program include GSK, Biogen Idec, and Novo Nordisk. These collaborations focus on antibody discovery, optimization, humanization, and bispecifics for therapeutic products.

09.26.13
Adimab Continues Roll-out of Its Technology Transfer Program with Novo Nordisk – 3rd Transfer in 2013

Lebanon, New Hampshire, USA – September 26, 2013 – Adimab, LLC, a leader in the discovery and optimization of fully human monoclonal and bispecific antibodies, today announced its 3rd technology transfer, by licensing the Adimab technology to Novo Nordisk. Adimab will receive upfront payments, annual licensing fees, and royalties on commercialized products resulting from Novo Nordisk’s use of the Adimab technology. Under the agreement, Novo Nordisk has been granted a non-exclusive license to use Adimab’s antibody platform for the discovery and optimization of antibodies.

By the first quarter of 2014, Adimab expects to have deployed its technology to three partner sites (GSK, Biogen Idec and Novo Nordisk). Adimab forecasts additional transfers throughout 2014, driven by the broad interest in its technology transfer program.

“We are pleased to have expanded our partnership with Novo Nordisk,” said Tillman Gerngross, Chief Executive Officer and Co-Founder of Adimab. “This is the third platform transfer this year, and this transaction with Novo Nordisk further validates our view that leading pharma companies have a need for better antibody discovery and optimization tools. At this point in time, our platform is the leading technology for antibody discovery and optimization, but, we haven’t rested on our laurels; we have over 25 people working on improving and expanding the platform’s capabilities to make sure that we stay ahead of the field.”

“We are very pleased to have established a broad relationship with Adimab,” said Hanne Risager Romedahl, Vice President of Novo Nordisk. “We feel confident that Adimab offers a comprehensive solution for our antibody discovery needs. In addition to using the platform as a rapid IgG discovery engine, we are particularly impressed with the ability to optimize antibodies with this broad protein engineering tool. This capability will nicely complement and enhance our existing antibody discovery technologies.”

Under the terms of the agreement, Novo Nordisk will have a non-exclusive field license to the Adimab antibody discovery platform and a unique custom antibody library that is exclusive to Novo Nordisk. Novo Nordisk is allowed to use the Adimab platform on an unlimited number of targets for IgG discovery, optimization, humanization and bispecifics. In addition, Novo Nordisk may access improvements to the platform during the term of the collaboration. Adimab will receive a series of payments including upfront payments, research and development milestones, plus royalties and commercial milestones on all therapeutic products generated from the Adimab platform.

“We are very proud that yet another Adimab partner has expanded into a broader relationship after seeing the output from the Adimab platform on several therapeutic projects,” said Guy Van Meter, VP of Business Development at Adimab. “This Novo Nordisk deal is another example of how we are able to structure terms around our partner’s needs and intended scope of use. We are looking forward to a productive partnership with Novo Nordisk.”

Over the past four years, Adimab has established numerous partnerships with leading pharmaceutical companies, including Merck, Roche, Novartis, Eli Lilly, Genentech, Biogen Idec, Novo Nordisk, Human Genome Sciences, Gilead, Kyowa Hakko Kirin, GSK, and Celgene. Adimab’s partnerships range from single-target funded discovery projects, to larger multi-target funded discovery collaborations. In 2013, Adimab started transferring its antibody discovery platform and custom antibody libraries to pharmaceutical companies for internal use. These collaborations focus on IgG discovery, optimization, humanization and/or bispecifics for therapeutic products.

08.20.13
Adimab Initiates New Therapeutic Discovery Partnership with Innovent

Lebanon, NH – August 20, 2013 – Adimab, LLC, a leader in the discovery of monoclonal and bispecific antibodies, and Innovent, a leading Chinese antibody therapeutics and manufacturing company, today announced a new partnership for the discovery, development and commercialization of an antibody-based therapeutic program. Under the terms of the agreement, Adimab will utilize its antibody discovery and optimization platform to identify a fully human therapeutic antibody against a target selected by Innovent. All initial product development, including manufacturing and clinical trials, will be coordinated by Innovent. Both companies will retain rights to develop and commercialize the therapeutic program in their respective geographic territories.

“We are excited to enter into this partnership with one of China’s leading biotechnology companies,” said Tillman Gerngross, Chief Executive Officer of Adimab. “Innovent’s manufacturing and product capabilities are impressive. They have built a remarkable manufacturing infrastructure and we are confident in their ability to develop attractive programs for the Chinese market.”

“Adimab is clearly a great strategic partner for Innovent. The speed and the quality of their platform has consistently generated therapeutic programs that are superior to the output from competing technologies,” said Michael Yu, Chief Executive Officer of Innovent. “We feel that combining the Adimab platform with Innovent’s strong development and manufacturing capabilities will help us to rapidly build a strong therapeutic pipeline and commercial presence in China.”

Under the terms of the agreement, the parties will jointly coordinate the development, manufacture and commercialization of the therapeutic antibody. Innovent will compensate Adimab for the discovery and optimization of the therapeutic leads. Innovent will initially lead the development efforts, including cell line development, formulation, manufacturing and clinical trials. Adimab is required to reimburse Innovent for specific development costs. Innovent will retain rights for commercialization in China, with royalties owed to Adimab on product sales. Adimab will retain rights for commercialization in the US, Europe and Japan, with royalties owed to Innovent on product sales.

In addition, Adimab today announced the achievement of technical milestones from its ongoing collaborations with Eli Lilly and Company, Gilead, and Kyowa Hakko Kirin.

Over the past four years, Adimab has established partnerships with multiple leading pharmaceutical companies, including Merck, Roche, Novartis, Lilly, Genentech, Biogen Idec, Novo Nordisk, Gilead, Kyowa Hakko Kirin, and GSK. Adimab’s partnerships range from single target funded discovery projects, to larger multi-target funded discovery collaborations, as well as full transfer and enablement of the Adimab Platform to pharmaceutical companies. These collaborations focus on IgG discovery, optimization, humanization and/or bispecifics for therapeutic products.

About Innovent Biologics
Innovent Biologics, Inc., a privately held biopharmaceutical company funded by Fidelity and Lilly from the US, is dedicated to the development and manufacturing of monoclonal antibodies and other biopharmaceuticals to be marketed in China and elsewhere around the world. Innovent has five products in development and is building the largest antibody production facility in China that complies with international standards.

08.20.13
Adimab Announces New Antibody Discovery Collaboration with Celgene Corporation

Lebanon, NH – August 20, 2013 – Adimab, LLC, a technology leader in the discovery of fully human antibodies, today announced a multi-target discovery collaboration with Celgene Corporation of Summit, NJ. Under terms of the Agreement, Adimab will use its proprietary platform to generate therapeutic antibodies against multiple targets. Celgene will have the right to develop and commercialize all therapeutic antibodies resulting from the collaboration.

“We are very pleased to announce another major pharma partnership,” said Tillman Gerngross, CEO and co-founder of Adimab. “Celgene has developed a highly successful oncology and inflammation franchise, and we are excited to partner with them to support their expanding antibody-based therapeutic portfolio.”

Adimab and Celgene have entered into a collaboration whereby Adimab will use its proprietary discovery and optimization platform to identify fully human antibodies against multiple targets. For each target, the agreement grants Celgene the right to research antibodies generated during the collaboration for potential use as therapeutic products. Under the terms of the Agreement, Adimab will receive an undisclosed upfront payment. In addition, for each target, Celgene will have the option to exclusively license antibodies generated during the collaboration. If Celgene exercises its option for a particular target, Adimab would receive license fees, clinical milestones and royalties on therapeutic product sales.

“The speed and technical superiority of our platform drives all of our deal flow,” said Guy Van Meter, Vice President of Business Development at Adimab. “The Adimab Platform is an extremely versatile antibody discovery and engineering tool that can be applied to a variety of different therapeutic development approaches, including IgG discovery, optimization, humanization, and bispecifics.”

Over the past four years, Adimab has established collaborations with multiple leading pharmaceutical companies, including Merck, Roche, Novartis, Eli Lilly, Genentech, Biogen Idec, Novo Nordisk, Gilead, Kyowa Hakko Kirin and GSK.

07.26.13
Adimab Announces 2nd Technology Transfer Agreement with Biogen Idec

Lebanon, NH – July 26th, 2013 – Adimab, LLC, a leader in the discovery of fully human monoclonal and bispecific antibodies, today announced an expanded collaboration with Biogen Idec for the discovery of antibody based therapeutics.

Under the terms of the agreement Adimab will license and transfer its proprietary antibody discovery platform (the “Adimab Platform”) to Biogen Idec and enable Biogen Idec researchers to utilize the Adimab technology for the discovery, optimization of all antibody formats, including bispecific antibodies. Following GSK, Biogen Idec will be the second pharmaceutical company to internalize the Adimab platform. Biogen Idec will receive a custom human antibody library that is unique and exclusive to Biogen Idec and will obtain a license to the Adimab Platform for use in Biogen Idec’s targeted therapeutic areas. In addition, Biogen Idec has secured an option to receive continued improvements to the Adimab Platform, including access to new antibody libraries. Adimab will receive an undisclosed upfront, signing fee, plus future payments upon achievement of specified preclinical and clinical milestones, as well as royalties and additional future payments upon achievement of specified commercial milestones on therapeutic products.

“We are excited to expand our relationship with Biogen Idec,” said Tillman Gerngross, Chief Executive Officer of Adimab. “Biogen Idec is one of the more sophisticated buyers in the industry, and having earned their endorsement through a competitive evaluation process validates our focus on offering the premier antibody discovery technology in the industry. The two BD teams worked hard to find the right structure to allow Biogen Idec to bring the Adimab technology in house.”

“This collaboration is the type of relationship we have been looking for. Our goal has always been to become the industry’s best technology provider for all antibody based therapeutics,” said Guy van Meter, VP of BD at Adimab. “As therapeutic programs get more complex and challenging, biotech and pharma companies need access to discovery technologies that can provide a competitive advantage.”

“The roots of Biogen Idec’s success are based in discovery science, and antibody biologic drug candidates are an important part of that,” said Werner Meier, Vice President of Biologics Drug Discovery at Biogen Idec. “In order to identify the best antibody discovery technology to support these efforts, we engaged in a rigorous selection process and Adimab was the clear winner. We believe Adimab’s platform will help us to accelerate our drug discovery efforts as we search for the next generation of antibodies to treat neurodegenerative and autoimmune diseases.”

Over the past four years, Adimab has established collaborations with multiple leading pharmaceutical companies, including Merck, Roche, Novartis, Eli Lilly, Genentech, Biogen Idec, Novo Nordisk, Gilead, Kyowa Hakko Kirin, and GSK. Adimab’s collaborations range from single target funded discovery projects, to larger multi-target funded discovery collaborations, as well as full license, transfer and enablement of the Adimab Platform to pharma companies. These collaborations focus on IgG discovery, optimization, humanization and/or bispecifics for therapeutic products.

07.26.13
Adimab Announces 1st Technology Transfer Agreement with GlaxoSmithKline

Lebanon, NH – July, 26th, 2013 – Adimab, LLC, a leader in the discovery of fully human monoclonal and bispecific antibodies, today announced its first platform technology transfer and license agreement with GlaxoSmithKline (GSK). Adimab to receive significant upfront payments, annual licensing fees, and royalties on resulting commercialized products. Under the agreement, GSK has been granted a non-exclusive license to use Adimab’s antibody platform for the discovery, and optimization of all antibody formats, including bispecific antibodies.

“Antibody therapeutics offer a tremendous opportunity to address diseases with serious unmet medical need,” said Tillman Gerngross, Chief Executive Officer and Co-Founder of Adimab. “Our platform dramatically reduces the preclinical development timelines and failure rates associated with existing technologies. This allows companies like GSK to get important protein based drugs into the clinic faster. With GSK’s commitment to protein based therapeutics, we expect them to broadly use the Adimab platform to discover, and optimize antibodies as well as generate improved bispecific molecules.”

“We surveyed the landscape of comparable technologies, and selected what we believe to be the world-leading antibody discovery and protein engineering platform to support our strategy of building a strong biopharmaceutical pipeline at GSK,” said Stephen Martin, Head of Biopharmaceuticals Discovery, GSK. “GSK is pleased to gain the first full access to this exciting platform, and the Adimab training and implementation team has shown a strong commitment to service and support. We had high expectations for the platform, and are very happy with the results to date. Adimab has been really collaborative and we’re looking forward to continuing this productive relationship.”

Under the terms of the agreement, GSK will have a broad license to the Adimab antibody discovery platform and a unique custom antibody library that is exclusive to GSK. In addition, GSK has secured an option to receive continued access to improvements to the Adimab antibody discovery platform, including access to subsequently-developed libraries. Adimab will receive a series of payments including a significant upfront cash payment, annual license fees and research and development milestones. Adimab will also receive royalties and commercial milestones on a defined number of therapeutic products.

“While the Adimab platform has attracted broad interest for more traditional discovery collaborations, finding the right approach for transferring the technology to a partner required some creativity. There are a variety of ways to structure these transactions. We worked closely with GSK to a find a structure that suited their needs,” said Guy Van Meter, VP of Business Development at Adimab. “Having a flexible approach will allow us to explore mutually beneficial structures based on the needs of the partner and the intended scope of use.”

Over the past four years, Adimab has established partnerships with multiple leading pharmaceutical companies, including Merck, Roche, Novartis, Eli Lilly, Genentech, Biogen Idec, Novo Nordisk, Human Genome Sciences, Gilead, and Kyowa Hakko Kirin. Adimab’s partnerships range from single-target funded discovery projects, to larger multi-target funded discovery collaborations, and now also include the transfer of the Adimab antibody discovery platform and custom antibody libraries to pharmaceutical companies. These collaborations focus on IgG discovery, optimization, humanization and/or bispecifics for therapeutic products.

01.08.13
Adimab Expands Collaborations with Merck and Lilly

Lebanon, NH – January 8, 2013 – Adimab, LLC, a technology leader in the discovery of fully human antibodies, today announced the expansion of its existing research collaborations with Merck and Lilly.

The latest agreement provides Merck expanded access to Adimab’s technology to discover and optimize fully human antibody candidates, including potentially bispecific antibody candidates, across all disease areas. Adimab scientists will discover therapeutic antibody candidates to multiple targets nominated by Merck over a three-year period.

“At Merck, we look at a lot of technologies and have been impressed with Adimab’s output in our previous collaboration,” said Deborah A. Law, vice president, Biologics Discovery, Merck Research Laboratories. “From a strategic perspective we wanted to maintain access to their technology.”

Adimab also announced the expansion of its existing research agreement with Lilly to include the discovery and optimization of multiple bispecific antibodies targeting molecular targets identified by Lilly.

Pursuant to these agreements with Merck, acting through a subsidiary, and Lilly, Adimab will receive upfront payments and is eligible to receive preclinical and clinical development milestone payments as well as royalties on product sales.

“We are always pleased when our existing partners choose to expand their relationship with us,” said Tillman Gerngross, Adimab’s CEO and co-founder. “The antibody discovery arena has become very competitive and nothing is more validating than existing partners coming back for broader access to our platform.”

“In addition to conventional discovery and optimization programs, we are seeing a lot of interest in our bispecific platform”, says Guy Van Meter, Vice President of Business Development at Adimab. “We continue to build on our leadership position in the antibody space, and I am pleased with the validation that these transactions provide for our bispecific antibody discovery and optimization capabilities.”

Over the past three years, Adimab has established collaborations with multiple leading pharmaceutical companies, including Merck, Roche, Novartis, Pfizer, Eli Lilly, Genentech, Biogen Idec, Novo Nordisk, Gilead and Kyowa Hakko Kirin.

01.07.13
Adimab Announces New Discovery Collaboration with Kyowa Hakko Kirin

Lebanon, NH – January 7, 2013 – Adimab, LLC, a technology leader in the discovery of fully human antibodies, today announced a two-target funded discovery collaboration with Kyowa Hakko Kirin (KHK) of Tokyo, Japan. Based on the strength and flexibility of Adimab’s platform, KHK has designated a membrane protein target as the initial collaboration target. In addition, Adimab announced the receipt of milestone payments from its existing collaborations with Gilead, Biogen Idec and Novo Nordisk.

“We are pleased to announce another major pharma partnership,” said Tillman Gerngross, CEO and co-founder of Adimab. “While other technology companies have diverted their focus by developing an internal pipeline of therapeutic products, we have committed all our resources to offering our customers the best discovery technology in the industry.”

Adimab and KHK have entered into a collaboration whereby Adimab will use its proprietary discovery and optimization platform to identify fully human antibodies against two targets selected by KHK. For each target, the agreement grants KHK the right to research antibodies generated from the collaboration for potential use as therapeutic products. Under the terms of the agreement, Adimab will receive various upfront fees including research fees and technical milestones. In addition, for each target, KHK will have the sole option to exclusively license antibodies from the collaboration, and if KHK were to exercise the option for a particular target, then Adimab would receive license fees, clinical milestones and royalties on therapeutic product sales for such target.

In addition, Adimab announced the achievement of technical milestones from its ongoing collaborations with Biogen Idec, Gilead, and Novo Nordisk.

“Adimab continues to see significant interest in our platform from new companies, and this is directly related to the success we have had in our existing partnerships,” said Guy Van Meter, Vice President of Business Development at Adimab. “Speed is always a factor in antibody discovery, but the ability to consistently deliver where other technologies have failed is just as important. Fortunately, we can do both.”

Over the past three and a half years, Adimab has established collaborations with multiple leading pharmaceutical companies, including Merck, Roche, Novartis, Pfizer, Eli Lilly, Genentech, Biogen Idec, Novo Nordisk, Gilead and Kyowa Hakko
Kirin.

08.01.12
Adimab and Mersana Announce Antibody-Drug Conjugate Alliance

Lebanon, NH and Cambridge, MA – August 1, 2012 – Adimab, LLC, the technology leader in the discovery and optimization of fully human therapeutic antibodies, and Mersana Therapeutics, Inc., a next-generation antibody-drug conjugate (ADC) company, today announced the initiation of a joint effort to offer integrated antibody discovery and ADC technologies. The alliance is built to offer pharmaceutical companies seamless access to Adimab’s world-class antibodies that have been specifically optimized for use in ADCs together with Mersana’s Fleximer polymer and broad array of customizable linkers for attaching diverse, potent payloads.

“We are excited to couple Mersana’s innovative ADC technology with our platform for use by the pharmaceutical industry. The flexibility in payloads, linkers and drug loading enabled by Mersana’s Fleximer technology complements Adimab’s philosophy of tailoring drug development to the biology of the target of interest,” said Adimab CEO Tillman Gerngross. “With this deal, Adimab is further expanding its footprint beyond monoclonal antibody discovery. We view ADCs, as well as other aspects of antibody discovery such as bispecific formats, as important tools in the development of novel therapeutics.”

“Over the past three years Adimab has established itself as the premier therapeutic antibody discovery company in the industry,” said Mersana CEO Nicholas Bacopoulos. "We are excited to combine Adimab’s technology with our highly differentiated ADC platform consisting of our clinically validated Fleximer polymer, diverse linkers and a wide variety of payloads. Adimab’s tailored approach fits perfectly with the customized design of Fleximer ADCs and together we can provide ADCs with increased likelihood of target selectivity and therapeutic efficacy. With our recently announced financing, this alliance represents a significant step forward in the company's transformation into a nextgeneration ADC company.”

About Adimab
Adimab’s fully integrated antibody discovery and optimization platform provides partners with the unique opportunity to readily incorporate biological assessments during the selection process. The availability of purified, full-length human IgGs allows for rapid determination of biologic function and potential therapeutic efficacy. Adimab offers fundamental advantages by delivering and optimizing diverse panels of therapeutically relevant antibodies that meet the most aggressive standards for affinity, epitope coverage, species cross-reactivity and developability.

With more than 30 antibody discovery projects in the last three years, Adimab has become the industry’s most sought after partner for the development of therapeutic human antibodies. Adimab has enabled its partners, including Biogen Idec, Eli Lilly, Genentech, Gilead, Human Genome Sciences, Merck, Novartis, Novo Nordisk, Pfizer, and Roche to expand their biologics pipelines through a range of technology access arrangements. Less than three years after Adimab launched its platform several antibodies discovered by Adimab have entered human clinical trials providing further evidence for the quality and speed of the platform. For more information, visit www.adimab.com.

About Mersana
Mersana engineers novel drug conjugates that maximize the potential of new and established therapeutic classes. Utilizing its proprietary conjugation technology, which is comprised of the Fleximer® polymer and a broad array of customizable linker chemistries, Mersana is developing a portfolio of nextgeneration antibody-drug conjugates (ADCs) with superior properties not found with other ADC technologies. Mersana is currently working with a number of top Pharma companies to develop next generation Fleximer-ADCs and most recently announced a $270 million collaboration with Endo Pharmaceuticals in March, 2012. The company is also advancing its own pipeline of next-generation drugs with best-in-class potential to address unmet needs and improve patient outcomes in multiple oncology indications. Mersana was founded by PureTech Ventures, LLC and a group of leading academics and clinicians.

For more information, visit www.mersana.com.

Fleximer® is a trademark of Mersana Therapeutics, Inc.

04.19.12
Adimab Announces New Antibody Discovery Program with Gilead and Initiates First Bispecific Antibody Collaboration

Lebanon, NH – April 19, 2012 – Adimab, LLC, a technology leader in the discovery of fully human therapeutic antibodies, today announced the initiation of two new independent research collaborations. Adimab and Gilead Sciences, Inc. (Nasdaq:GILD) of Foster City, CA, have initiated a research collaboration to identify therapeutic antibodies against two targets selected by Gilead. In addition, Adimab has expanded one of its current partnerships to initiate a new project in the area of bispecific antibodies. Adimab today announced the achievement of several technical milestones from its ongoing collaborations with Novartis, Merck, Merrimack, and Genentech.

With more than 28 antibody discovery projects in the last three years, Adimab has become the industry’s most sought after partner for the development of therapeutic human antibodies. Adimab has enabled its partners, including Biogen Idec, Eli Lilly, Genentech, Gilead, Human Genome Sciences, Merck, Novartis, Novo Nordisk, Pfizer, and Roche to expand their biologics pipelines through a range of technology access arrangements. Less than three years after Adimab launched its platform several antibodies discovered by Adimab have entered human clinical trials providing further evidence for the quality and speed of the platform.

"Since inception, Adimab has focused on building the best-in-class antibody discovery technology. The ongoing demand from partners and development progress with our candidates clearly demonstrates the achievement of that goal,” stated Tillman Gerngross, PhD, CEO of Adimab. "We are now expanding our platform into other aspects of antibody discovery, including bispecific and multi-specific formats. Further, Adimab’s significant investment in cell-based selections is starting to pay off and we have begun deploying those capabilities in ongoing customer campaigns with considerable success."

“Adimab seeks to be the partner of choice in antibody discovery by providing its collaborators with the highest quality development candidates and making its technology available through flexible technology access arrangements,” explained Guy Van Meter, VP of Business Development. “With the first antibodies discovered by Adimab in the clinic, we are now applying our technology to bispecific partnerships with the ultimate goal of becoming a onestop shop for all antibody-related discovery needs.”

About the New Collaborations
Adimab and Gilead have initiated a research program whereby Adimab will use its proprietary discovery platform to identify fully human antibodies against up to two targets selected by Gilead. The agreement gives Gilead the option to commercialize antibodies generated from the collaboration. Adimab will receive upfront payments and preclinical milestones. In addition, Adimab is eligible to receive clinical development milestones and royalties on product sales.

Adimab and an undisclosed partner have initiated a joint research program whereby Adimab will use its proprietary discovery platform to identify bispecific antibodies that bind two distinct targets selected by the partner. The agreement gives the partner the option to commercialize one or more of the bispecific antibodies generated from the collaboration. Adimab is eligible to receive technical milestones, license fees, clinical development milestones and royalties on product sales.

04.02.12
Adimab Completes Series F Financing – Acquires New Research Facility to Accommodate Growth

Lebanon, NH – April 2, 2012 – Adimab, LLC, a leader in the discovery of fully human antibodies, today announced the closing of an over-subscribed Series F financing. The additional funds were raised entirely from existing investors. In addition, Adimab has acquired a new 21,500 square foot research facility at 7 Lucent Drive in Lebanon, NH. The building will serve as the company’s headquarters.

“These additional funds enhance our already strong balance sheet, allowing us to pursue several complementary opportunities more aggressively,” said Tillman Gerngross, Chief Executive Officer of Adimab. “We are accelerating the expansion of our platform to include additional applications such as the development of bi-specific antibodies, antibody-drug conjugates, targeting cell based antigens including GPCRs and ion channels, as well as preclinical manufacturing and mammalian cell line development.”

“Our focus has always been on helping our partners develop better therapeutic antibodies. Therefore, as we see attractive opportunities to acquire or develop additional capabilities we want to have excess capital to pursue them. Based on the strength of our current business we were able to raise capital under very attractive terms, which made this an easy decision,” said Errik Anderson, Chief Operating Officer of Adimab.

About Adimab
Adimab’s fully integrated antibody discovery and optimization platform provides partners with the unique opportunity to rapidly incorporate biology while selecting purified, full-length human IgGs. As a result, Adimab offers fundamental advantages by delivering and optimizing diverse panels of therapeutically relevant antibodies that meet the most aggressive standards for affinity, epitope coverage, species cross-reactivity and developability.

As a result of its robust next-generation antibody discovery and optimization technology, Adimab has become the industry’s most sought after partner, having collaborated on more than 20 antibody discovery projects in the last three years. Adimab enables its partners, including Biogen Idec, Genentech, Lilly, Merck, Novartis, Novo Nordisk, Pfizer, Roche, and others, to rapidly expand their biologics pipelines through a broad spectrum of technology access arrangements. The quality and speed of Adimab’s platform have been further validated by the use of several Adimab-discovered antibodies in human clinical testing less than three years after Adimab launched its platform. For more information, visit www.adimab.com.

01.11.12
Three Adimab Antibodies Enter Human Clinical Trials

Lebanon, NH – January 11, 2012 – Adimab, LLC, a leader in the discovery of fully human antibodies, today announced that its partner, Merrimack
Pharmaceuticals, Inc. of Cambridge, MA, has initiated the first human clinical trial of MM-151, an oligoclonal therapeutic consisting of a mixture of three fully human monoclonal antibodies designed to bind to non-overlapping epitopes of the epidermal growth factor receptor (EGFR). The three lead antibodies and a number of backups were discovered by Adimab and licensed exclusively to Merrimack.

“We launched our platform two and a half years ago and are now seeing the first programs enter the clinic,” said Tillman Gerngross, Adimab’s CEO. “Merrimack had a validated target and an understanding of the biology necessary for a novel antibody therapeutic.”

At the end of 2009, Adimab and Merrimack entered into a collaboration whereby Adimab used its proprietary yeast-based antibody discovery platform to discover fully human antibodies against human EGFR that were also cross-reactive with the murine and rhesus forms of the antigen. Adimab delivered the first panel of leads within twelve weeks of project initiation and several leads and backups were further optimized.

“This was a challenging program because our partner was looking for something very specific – three mutually exclusive epitopes, picomolar affinities and the ability to effectively block ligand interaction,” said Michael Feldhaus, EVP of Research at Adimab.

“Anyone in the antibody discovery business can give you binders to an antigen,” explained Gerngross. “Adimab gives you control over the discovery and optimization process that is unparalleled in our field – the relevant output is a therapeutic not just a binder.”

01.05.12
Adimab Expands Executive Team with Addition of Philip T. Chase as General Counsel Guy Van Meter Promoted to Vice President of Business Development

Lebanon, NH – January 5, 2012 – Adimab, LLC, a leader in the discovery of fully human antibodies, today announced that Philip T. Chase has joined the company as General Counsel. Mr. Chase comes to Adimab with extensive legal and dealmaking experience in the biotechnology industry. Most recently, Mr. Chase served as the General Counsel at Alnylam Pharmaceuticals where he oversaw all legal functions during a time when Alnylam executed and managed numerous significant partnerships, including large technology collaborations with Roche and Takeda.

“We are very pleased to add an individual as experienced as Phil to our executive management team,” said Errik Anderson, Adimab’s Co-Founder and Chief Operating Officer. “Phil’s involvement with strategic technology partnerships and alliance management at Alnylam and Transkaryotic Therapies will add depth and capabilities as we execute on Adimab’s strategy.”

In addition, Adimab today announced the promotion of Guy Van Meter to Vice President, Head of Business Development, with responsibility for all business development activities at Adimab.

“For the past 3 years, Guy has been driving our business development efforts and has been instrumental in establishing partnerships with Merck, Roche, Pfizer, Novartis, Lilly, Genentech, Biogen Idec, Novo Nordisk, and others,” explained Tillman Gerngross, Adimab’s Co-Founder and Chief Executive Officer. “This promotion both recognizes Guy’s past contributions to Adimab, as well as expands his responsibility to structuring longer term strategic partnerships that may involve broad access to Adimab’s antibody discovery platform.”

About Philip T. Chase
Prior to Adimab, Mr. Chase served as the General Counsel at Alnylam
Pharmaceuticals where he oversaw all legal functions and had a prominent role in
Alnylam’s business development activities. Before that, Mr. Chase served as Vice President and General Counsel of EPIX Pharmaceuticals, Inc. and played an integral role in the merger of EPIX and Predix Pharmaceuticals Holdings, Inc. Mr.

Chase also served as Chief Corporate Counsel at Transkaryotic Therapies, Inc. and played an integral role in the sale of that company to Shire plc. Prior to moving into the biotechnology industry, Mr. Chase worked at the law firms of Skadden, Arps, Slate, Meagher & Flom LLP, and Shearman & Sterling LLP. He received his J.D. degree from Columbia University School of Law and his BA from Colby College.

About Guy Van Meter
Mr. Van Meter has served as Senior Director of Business Development for Adimab for the past 3 years. Prior to Adimab, Mr. Van Meter was in a business development and strategic alliance role at Pfizer within the Pfizer Biotherapeutics and Bioinnovation Center. Mr. Van Meter has also served in business development at Dyax Corp. where he managed the technology licensing business. Prior work experience includes a regulatory product development role at Alkermes, Inc., and research at Harvard-Brigham and Women’s and Yale University School of Medicine. Mr. Van Meter holds an MBA from the F.W. Olin Graduate School of Business at Babson College.

08.29.11
Adimab Announces New Discovery Programs with Biogen Idec and Novo Nordisk

Lebanon, NH – August 29, 2011 – Adimab, LLC, a technology leader in the discovery of fully human antibodies, today announced the initiation of two independent collaborations with Biogen Idec and Novo Nordisk. Over the past two years, Adimab has established collaborations with multiple leading pharmaceutical companies, including: Merck, Roche, Novartis, Pfizer, Eli Lilly, Genentech, Human Genome Sciences, and now Biogen Idec and Novo Nordisk.

“Adimab is increasingly recognized as the premier antibody discovery technology in the industry,” said Tillman Gerngross, Adimab’s CEO and co-founder. “Our partners are looking for technologies that improve the lead discovery process and enhance their ability to quickly move novel antibodies into the clinic. Our technology is simply faster, dramatically reduces the risk of development failures, and generates higher quality leads even against challenging targets; in fact many of our partners come to us with targets that have failed using traditional phage display approaches.”

In addition to the two new collaborations, Adimab today announced the achievement of several technical milestones from its ongoing collaborations with Merck, Novartis, Pfizer and Human Genome Sciences. Adimab also announced that Merrimack Pharmaceuticals has exercised a commercial license for a therapeutic program (MM-151), which is scheduled to enter the clinic in the fall of 2011.

“The quality of our technology will always be the main driver for generating new collaborations, but our pharma partners are increasingly looking for unrestricted long-term access,” said Guy Van Meter, Adimab’s Senior Director of Business Development. “Adimab’s platform, unlike many other antibody discovery platforms, is free from target restrictions. In addition, Adimab provides its pharma partners with their own unique library diversity that is different from what their competitors have. Adimab’s ability to transfer that capability to them has generated considerable interest in the industry.”

Adimab and Biogen Idec (NASDAQ: BIIB), of Weston, MA, have initiated a research program whereby Adimab will use its proprietary discovery platform to identify fully human antibodies against two targets selected by Biogen Idec. The agreement gives Biogen Idec the option to commercialize antibodies generated from the collaboration. Adimab will receive upfront payments and preclinical milestones. In addition, Adimab is eligible to receive clinical development milestones and royalties on product sales.

Adimab and Novo Nordisk (NYSE: NVO), of Denmark, have initiated a research program whereby Adimab will use its proprietary discovery platform to identify fully human antibodies against two targets selected by Novo Nordisk. The agreement gives Novo Nordisk the option to commercialize antibodies generated from the collaboration. Adimab will receive upfront payments and preclinical milestones. In addition, Adimab is eligible to receive clinical development milestones and royalties on product sales.

12.15.10
Adimab Announces New Discovery Programs with Eli Lilly, Genentech and Human Genome Sciences

Lebanon, NH - December 15, 2010 - Adimab, Inc., a technology leader in the discovery of fully human antibodies, today announced the initiation of th ree new independent research collaborations with Eli Lilly, Genentech, and Human Genome Sciences. Over the past 18 months Adimab has established collaborations with several leading Pharmaceutical companies including: Merck, Roche, Novartis, Pfizer, and now Eli Lilly, Genentech, and Human Genome Sciences.

"As more companies develop therapeutic leads against the same validated disease targets, leading Pharma companies are actively seeking out technologies that give them a meaningful advantage and Adimab's deal flow speaks for itself," said Tillman Gerngross, Adimab's CEO and co-founder. "In this highly competitive environment, having access to the best technology becomes essential, not optional. Our ability to provide high quality leads in a matter of months is driving the demand for our technology."

In addition to the three new collaborations, Adimab announced the achievement of a technical milestone in its ongoing collaboration with Novartis, which was initiated in June of 2010. Adimab also announced that Merck has exercised its option to start an additional project around a 2nd target. "Adimab's platform is unique in comparison to any other antibody discovery technology. By incorporating target biology into the selection process we are able to generate very high quality leads in a short timeframe," said Guy Van Meter, Adimab's Senior Director of Business Development. "The most sophisticated buyers in the industry understand the impact Adimab could have on their pipelines. Since launching the platform in June of 2009, we have closed a total of 15 funded discovery programs, including 10 new programs in 2010."

About Adimab's New Discovery Deals
Adimab and Lilly have entered into a collaboration whereby Adimab will use its proprietary discovery platform to identify fully human antibodies against two targets selected by Lilly. For each target, the agreement grants Lilly the right to research antibodies generated from the collaboration for potential use as therapeutic products. Under the terms of the agreement, Adimab will receive various upfront fees including research fees and technical milestones. In addition, for each target, Lilly will have the sole option to exclusively license antibodies from the collaboration, and if Lilly were to exercise the option for a particular target, then Adimab would receive license fees, clinical milestones and royalties on therapeutic product sales for such target.

Adimab and Genentech, Inc., a member of the Roche Group (SIX: RO, ROG; OTCOX: RHHBY) have initiated a research program whereby Adimab will use its proprietary yeast-based antibody discovery platform to identify fully human antibodies against two targets selected by Genentech. Under the terms of the agreement, Genentech has rights to commercialize antibodies generated from the collaboration. Adimab will receive upfront payments, preclinical milestones and licensing fees. In addition, Adimab is eligible to receive clinical development milestones and royalties on therapeutic and diagnostic product sales.

Adimab and Human Genome Sciences, of Rockville MD, have initiated a research program whereby Adimab will use its proprietary discovery platform to identify fully human antibodies against one target selected by Human Genome Sciences. The agreement gives Human Genome Sciences the option to commercialize antibodies generated from the collaboration. Adimab will receive upfront payments and preclinical milestones. In addition, Adimab is eligible to receive clinical development milestones and royalties on product sales.

09.15.10
Adimab makes FierceBiotech's "Fierce 15" List for 2010

Lebanon, NH – September 15, 2010 – Adimab, Inc., a leader in the discovery of fully human antibodies, today announced it was named by FierceBiotech as one of 2010’s Fierce 15, designating it as one of the most promising private biotechnology companies in the industry. Every year FierceBiotech evaluates hundreds of private companies for its annual list, which is based on a variety of factors such as the strength of its technology, partnerships and a competitive market position. A complete list of “Fierce 15” companies is available online at www.fiercebiotech.com.

“In little more than a year Adimab has signed up four of the biggest names in biopharma as collaborators: Merck, Pfizer, Novartis and Roche,” says John Carroll, editor of FierceBiotech. “All have gone to the Lebanon, NH-based biotech--run by the savvy Dartmouth Professor Tillman Gerngross--in search of a quicker, surer way to get their hands on promising new antibody drug candidates. And the highly focused biotech company expects more--and much, much bigger-deals to follow.”

“We very much appreciate the recognition by Fierce Biotech, and realize that we receive this award because the ultimate judges of our technology, our pharma partners, have voted with their feet. Antibody discovery is a mature field, therefore any new technology needs to be demonstrably superior to establish a leadership position in such a short period of time,” comments Tillman Gerngross, PhD, co–founder and CEO of Adimab. “Our partnerships are structured to provide unencumbered strategic access to the industry’s premier antibody discovery platform, and the award reflects the progress we have made on the business development front in the last year.”

About FierceBiotech
FierceBiotech is the biotech industry's daily monitor - a free email newsletter and web resource providing the latest biotech news, articles, and resources related to clinical trials, drug discovery, FDA approval and regulation, biotech company deals and more. More than 75,000 top biotech professionals rely on FierceBiotech for an insider briefing on the day’s top stories. Sign up is free at http://www.fiercebiotech.com.

09.01.10
Adimab Selected as Technology Pioneer 2011 by World Economic Forum

Lebanon, NH – September 1, 2010 – The World Economic Forum today announced that Adimab has been selected as a 2011 Technology Pioneer. To be selected as a World Economic Forum Technology Pioneer, a company must be involved in the development of a major technology or innovation and have the potential for long-term impact on business and society. In addition, Technology Pioneers must demonstrate visionary leadership and show the signs of being a longstanding and sustainable market leader with a commercially validated technology.

“Adimab is pleased to earn the World Economic Forum’s recognition as a Technology Pioneer. Our vision has always been to provide leading Pharma and Biotech companies with broad availability to our human antibody discovery platform,” commented Tillman Gerngross, PhD, co– founder and CEO of Adimab. “We expect to significantly and positively impact healthcare by discovering better therapeutics and reducing development timelines and costs for our expanding roster of drug development partners.”

“The speed, diversity and efficiency of Adimab’s technology enable a unique business model for a drug discovery company,” said Errik Anderson, Adimab’s COO. “Our flexible licensing model allows us to provide multiple parties with unencumbered strategic access to the world’s premier human antibody discovery platform thus fueling profitable and self-sustaining operations.”

Adimab is one of 5 companies in the life sciences sector and one of 31 companies receiving the honor overall. The identification of the World Economic Forum 2011 Technology Pioneers is the result of a rigorous selection process. The Forum received more than 330 applications from around the world which were evaluated by 68 global technology experts. The 31 Technology Pioneers 2011 will share ideas and visions for the 21st century during the World Economic Forum Annual Meeting 2011 in Davos Switzerland.

For more information about the World Economic Forum Technology Pioneers Program, please visit: http://www.weforum.org/techpioneers.

For more information about Adimab, please visit: http://www.adimab.com/.

07.09.10
Adimab Announces Fifth Major Pharmaceutical Partnership in First Year After Launch of Novel Antibody Discovery Platform

Lebanon, NH – July 9, 2010 – Adimab, Inc., a leader in the discovery of fully human antibodies, today announced the initiation of a research collaboration with Novartis (Basel, Switzerland). This agreement represents the fifth major partnership Adimab has announced since launching its platform at BIO 2009 in Atlanta, just one year ago. In addition, Adimab today announced the receipt of a second milestone payment from its ongoing collaboration with Merck and Co.

“Adimab’s ability to generate high quality therapeutic leads in less than three months reduces much of the uncertainty of preclinical development and translates into a fundamental competitive advantage for our collaborators,” comments Tillman Gerngross, PhD, co–founder and CEO of Adimab.

In the first year after the launch of its antibody discovery platform, Adimab has entered into discovery partnerships with some of the world’s premier pharmaceutical companies including Merck, Roche, Pfizer and Novartis. Further, Adimab has received numerous payments related to the successful achievement of key technical milestones in these programs. “With current announced and unannounced contracts, continued revenue from milestone payments and broad interest around Adimab’s platform, we expect 2010 to be our first profitable year,” notes Errik Anderson, COO of Adimab.

About the Adimab - Novartis Collaboration
Adimab and Novartis, of Basel, Switzerland, have initiated a research program whereby Adimab will use its proprietary discovery platform to identify fully human antibodies against two targets selected by Novartis. The agreement gives Novartis rights to commercialize antibodies generated from the collaboration. Adimab will receive upfront payments, preclinical milestones and licensing fees. In addition, Adimab is eligible to receive clinical development milestones and royalties on therapeutic and diagnostic product sales.

“Most pharma companies currently have access to one or more antibody technologies, therefore the success of a new platform requires significant technical and business advantages. The quality of our output, combined with our ability to reduce complex business issues, such as gatekeeping and burdensome royalty obligations, are key aspects to driving broader collaborations with pharma companies,” says Guy van Meter, Senior Director of Business Development of Adimab. “Based on our early success, we believe that Adimab’s technology will continue to be in high demand and we are in active discussions with several partners regarding broader unencumbered access and technology transfer."

12.17.09
Adimab Announces New Antibody Discovery Collaborations with Pfizer and an Unnamed Partner and Achievement of Milestones in Existing Partnerships with Roche and Merck

Lebanon, NH – December 17, 2009 – Adimab, Inc., a leader in the discovery of fully human antibodies, today announced the initiation of research collaborations with Pfizer and an undisclosed second company. Adimab also announced the receipt of milestone payments from two recently announced discovery collaborations with Merck and Roche.

“Adimab’s discovery technology has distinct and quantifiable advantages over any other technology in the industry – our speed, epitopic coverage and quality of output are unmatched and this has created a very attractive business environment for us,” said Guy van Meter, Senior Director of Business Development. “Our partnering success demonstrates that leading pharmaceutical companies are starting to recognize the advantages of our platform and, based on the strong interest, we expect this momentum to continue into 2010.”

The two newly executed collaborations are funded discovery programs whereby Adimab will utilize its proprietary antibody discovery platform to identify therapeutic leads to targets designated by its partners. A summary of the new collaborations follows:

• Adimab and Pfizer, of New York, NY, have initiated a research program whereby Adimab will use its proprietary discovery platform to identify fully human antibodies against one Central Nervous System/Pain target selected by Pfizer. The agreement gives Pfizer rights to commercialize antibodies generated from the collaboration. Adimab will receive upfront payments. In addition, Adimab is eligible to receive preclinical milestones, clinical development milestones, commercial milestones, licensing fees and royalties on therapeutic and diagnostic product sales.

• Also in a separate agreement, Adimab and an undisclosed company have initiated a research program whereby Adimab will use its proprietary discovery platform to identify fully human antibodies against one oncology target selected by the undisclosed company. The agreement gives the undisclosed company rights to commercialize antibodies generated from the collaboration. Adimab will receive upfront payments, preclinical milestones and licensing fees. In addition, Adimab is eligible to receive clinical development milestones, commercial milestones and royalties on therapeutic and diagnostic product sales.

“Since launching the platform in June we have experienced continued interest from most major pharmaceutical companies,” said Tillman Gerngross, Adimab’s CEO and co-founder. “It is simply the quality of our science and the dramatically better output that drives the interest. Today’s announcement shows that we are able to deliver on our earlier collaborations, and sustain the deal flow we have projected since launching the platform earlier in the summer. We expect this momentum to carry solidly into 2010”, Gerngross adds.

In addition to the two new collaborations, Adimab announced the achievement of milestone payments from its ongoing collaborations with Merck and Roche, both of which were announced in June 2009. A summary of the milestones follows:

• Merck confirmed delivery of a panel of antibodies that met criteria outlined in the original agreement within 8 weeks of the initiation of the discovery program.
• Roche confirmed the successful delivery of several hundred IgGs within 8 weeks of starting an antibody discovery program with Adimab. The IgGs delivered met specific criteria as outlined in the contract.

10.01.09
Adimab Completes Series D Financing Led by Google Ventures

Lebanon, NH – October 1, 2009 – Adimab, Inc., a world leader in human antibody discovery, today announced the closing of a Series D financing led by Google Ventures with participation by previous investors Polaris Ventures, SV Life Sciences, OrbiMed Advisors and Borealis Ventures. Bill Maris of Google Ventures will join Adimab's Board of Directors. The total amount of the financing was not disclosed.

"Cutting-edge life science technologies are extremely computationally intensive, and Google Ventures will contribute valuable input as Adimab works to become the world's leading antibody discovery company”, said Bill Maris, Managing Partner at Google Ventures. “Adimab's technology is truly groundbreaking, and we are thrilled to join their existing investors to support the company’s growth.”

“Adimab reviewed multiple investment proposals but it was clear that Google Ventures immediately understood our value proposition - that a prolific discovery platform can drive even greater productivity when integrated with advanced computational tools,” says Errik Anderson, Chief Operating Officer at Adimab. “The continued support of our previous investor base is also testament to the strength of this proposition.”

“OrbiMed has been impressed by Adimab’s ability to consistently execute ahead of schedule as exemplified by their successful development of a best-in-class antibody discovery platform less than three years from inception,” said Carl Gordon, Ph.D., CFA, General Partner and Co-Head of Private Equity at OrbiMed Advisors. “The company’s recent partnerships with Merck and Roche are just another validation of this platform.”

“I believe that the recipe for success is based on a simple formula: outstanding management teams with outstanding technologies going after important opportunities. Adimab has all three key components and, as a direct result, has been able to raise capital at another valuation uptick,” said Terry McGuire, Managing General Partner at Polaris Ventures. "Adimab is one of the stars in our portfolio and we are thrilled to be an investor."

"As life science investors we rarely see companies whose base technology even meets our original expectations. In short time, Adimab has already far exceeded our initial technical goals and is rapidly changing the technological landscape of antibody discovery,” said Mike Ross, Ph.D., Managing General Partner at SV Life Sciences.

About Google Ventures
Google Ventures seeks to discover and grow great companies - we believe in the power of entrepreneurs to do amazing things. We're studying a broad range of industries, including consumer Internet, software, hardware, clean-tech, bio-tech and health care. We invest anywhere from seed to late stage, and embrace the challenge of helping young companies grow from the garage to global relevance. Our team includes entrepreneurs, investors and innovators, along with some 20,000+ exceptional Googlers whose breadth of knowledge, experience and creativity constitute perhaps our most valuable resource. For more information, visit www.google.com/ventures.

About Borealis Ventures
Borealis Ventures is an early-stage venture capital firm that partners hands-on with founders to build compelling companies from the earliest stages. We are based in New Hampshire, but our portfolio companies here and beyond have global impact as they commercialize technologies that advance human health, redefine application software, and deliver pioneering Internet and mobile services to new audiences.

About OrbiMed Advisors
OrbiMed is the world’s largest life sciences and healthcare-dedicated investment firm, with approximately $5 billion in assets under management. Since inception of its private equity investment activities in 1993, OrbiMed has successfully invested in close to 100 companies across a wide range of therapeutic categories and stages of development. OrbiMed’s investment team includes approximately 30 experienced professionals with backgrounds in science, medicine, industry, finance and law. OrbiMed’s professionals work together using a collaborative, team-oriented approach to support our portfolio companies, which has earned OrbiMed a reputation as a capital provider of choice for life sciences companies of all stages.

About Polaris Venture Partners
Polaris Venture Partners is a partnership of experienced private equity investors, operating executives and entrepreneurs. The firm's mission is to identify, invest in and partner with seed, early stage, and middle market businesses with exceptional promise and help them grow into market-leading companies. The firm has over $3 billion under management, more than 20 investment professionals, and current investments in more than 75 companies.

About SV Life Sciences
SV Life Sciences is a venture capital fund providing financing to businesses at all stages of development across the human life sciences sector, including biotechnology, pharmaceuticals, medical devices and instruments, and healthcare information technology and services. SV Life
Sciences currently manages or advises five funds with capital commitments of approximately
$1.6 billion.

06.16.09
Adimab Launches Novel Antibody Discovery Platform and Announces Discovery Programs with Merck and Roche

Lebanon, NH – June 16, 2009 – Adimab, Inc., an emerging leader in the discovery of fully human antibodies, today announced the launch of a unique human antibody discovery platform based on the first fully synthetic human pre-immune IgG repertoire. Adimab’s yeast-based platform offers unprecedented epitope coverage and allows for the discovery of high affinity fulllength human IgGs in extremely rapid timeframes. In addition, Adimab announced two major research collaborations.

Adimab and Merck, of Whitehouse Station, NJ, have entered into a collaboration whereby Adimab will use its proprietary yeast-based antibody discovery platform to identify fully human antibodies against targets selected by Merck. The agreement grants Merck the right to commercialize antibodies generated from the collaboration as therapeutic products.

In a separate deal, Adimab and Roche, of Basel, Switzerland, have initiated a research program whereby Adimab will use its proprietary yeast-based antibody discovery platform to identify fully human antibodies against a target selected by Roche. The agreement allows Roche the right to commercialize antibodies generated from the collaboration as therapeutic and diagnostic products.

Under the terms of the agreements, Adimab will receive various upfront payments, preclinical milestones and licensing fees. In addition, Adimab is eligible to receive clinical development milestones, commercial milestones and royalties on therapeutic and diagnostic product sales.

“Adimab has developed a disruptive technology in the antibody discovery space,” said Tillman Gerngross, Adimab’s CEO and co-founder. “The speed, robustness and diversity of our platform will provide drug developers with meaningful advantages over current discovery technologies and we believe this approach has the potential to become a new standard in the industry.”

”The execution of discovery agreements with two of the top ten pharmaceutical companies based on Adimab’s platform underscores the demand for novel technical approaches and more flexible business solutions in antibody discovery,” stated Guy van Meter, Senior Director of Business Development. “We are continuing to get significant traction with potential collaborators and expect the partnering momentum to continue in 2009.”

11.20.08
Adimab, Inc. Announces Series C Financing

Lebanon, NH – November 20, 2008 – Adimab, Inc., a leading antibody discovery company, today announced the closing of a Series C financing. The total amount of the financing was not disclosed.

The investment reflects strong support from new investors OrbiMed Advisors and Borealis Ventures, as well as existing investors Polaris Venture Partners and SV Life Sciences. “Proceeds from the financing will be used to increase the capacity for conducting multiple parallel discovery programs as well as automating several aspects of our antibody discovery process,” described Errik Anderson, Vice President of Operations and Finance.

“Raising capital at this step-up in valuation reflects Adimab’s progression from an early concept to a robust antibody discovery and maturation platform,” said Tillman Gerngross, Ph.D., Chief Executive Officer and Co-founder. “We now have the ability to go from antigen to a large panel of high affinity, fully-human antibodies in a matter of weeks.”

“OrbiMed has invested in several leading antibody discovery companies over the years, and we believe that Adimab has assembled a truly unique and compelling next-generation antibody discovery platform,” said Carl Gordon, Ph.D., CFA, General Partner and Co-Head of Private Equity at OrbiMed Advisors. “We invest in exceptional entrepreneurs and management teams combined with strong science, and we are thrilled to back Gerngross and Wittrup in their latest endeavor.”

“We’ve had the privilege to work with Dr. Gerngross before and have closely followed Adimab’s development,” said Phil Ferneau, Managing Director of Borealis Ventures. “Beyond the depth of its intellectual property strategy, what sets Adimab apart is the team’s laser-focus on addressing the needs of their pharma partners.”

“The fact that Adimab is able to raise money with such an up-tick in valuation, in this challenging environment, is a testament to the quality of Adimab’s technology and the team running the company,” said Terry McGuire, Managing General Partner of Polaris Ventures.

“What they have accomplished in this short period of time is remarkable and anybody in the business of developing antibodies should pay close attention – these guys are rapidly changing the technological landscape of antibody discovery,” said Mike Ross, Ph.D., Managing General Partner at SV Life Sciences in Boston.

About Borealis Ventures
Borealis Ventures is an early-stage venture capital firm that partners hands-on with founders to build compelling companies from the earliest stages. We are based in New Hampshire, but our portfolio companies here and beyond have global impact as they commercialize technologies that advance human health, redefine application software, and deliver pioneering Internet and mobile services to new audiences.

About OrbiMed Advisors
OrbiMed is the world’s largest life sciences and healthcare-dedicated investment firm, with approximately $5 billion in assets under management. Since inception of its private equity investment activities in 1993, OrbiMed has successfully invested in close to 100 companies across a wide range of therapeutic categories and stages of development. OrbiMed’s investment team includes approximately 30 experienced professionals with backgrounds in science, medicine, industry, finance and law. OrbiMed’s professionals work together using a collaborative, team-oriented approach to support our portfolio companies, which has earned OrbiMed a reputation as a capital provider of choice for life sciences companies of all stages.

About Polaris Venture Partners
Polaris Venture Partners is a partnership of experienced private equity investors, operating executives and entrepreneurs. The firm's mission is to identify, invest in and partner with seed, early stage, and middle market businesses with exceptional promise and help them grow into market-leading companies. The firm has over $3 billion under management, more than 20 investment professionals, and current investments in more than 75 companies.

About SV Life Sciences
SV Life Sciences is a venture capital fund providing financing to businesses at all stages of development across the human life sciences sector, including biotechnology, pharmaceuticals, medical devices and instruments, and healthcare information technology and services. SV Life Sciences currently manages or advises five funds with capital commitments of approximately $1.6 billion.

10.24.08
Guy Van Meter joins Adimab, Inc. as Senior Director, Head of Business Development

Lebanon, NH – October 24, 2008 – Adimab, Inc., a biotechnology company developing an integrated yeast-based antibody discovery and maturation platform, today announced the appointment of Guy Van Meter as Senior Director, Head of Business Development. Mr. Van Meter comes to Adimab from a business development role at Pfizer Inc, where he was involved in new business initiatives around RNAi therapeutics and regenerative medicine for Pfizer’s Biotherapeutics and Bioinnovation Center in San Francisco.

Prior to Pfizer, Mr. Van Meter spent 6 years in business development at Dyax Corp, including managing Dyax’s successful phage display licensing program. At Dyax, he established more than 45 revenue-generating collaborations with companies in the United States, Europe, India, Australia, and Japan, including Amgen, Boehringer-Ingelheim, Merck-Serono, and ImClone.

Prior to Dyax, Mr. Van Meter held regulatory and research roles at Alkermes, Inc, and conducted research at Harvard’s Brigham and Women’s and Yale University. He graduated from the Olin Graduate School of Business at Babson College in 2002.

“Adimab is at a critical juncture where the number of potential collaborations exceeds our current capacity,” said Tillman Gerngross Ph.D., Adimab’s co-founder and Chief Executive Officer. ”Managing multiple relationships with several large companies and ensuring a quality experience is of great importance to us. Guy Van Meter comes to Adimab with a wealth of experience in Business Development, in particular in the antibody space, and we are delighted to have him join the team.”

“Adimab is one of the most impressive companies to enter the antibody technology space in some time,” said Mr. Van Meter. "The company’s approach is clearly unique and provides advantages over all existing technologies. I am very pleased to joining a company with such an experienced management team and talented scientists. It is an exciting time.”

03.25.08
Adimab, Inc. announces Series B Financing – Polaris and SV Life Sciences co-lead the investment

Lebanon, NH – March 25, 2008 – Adimab, Inc., a biotechnology company developing a human antibody discovery platform in yeast, today announced the closing of Series B financing. The total amount of the financing was not disclosed. The round was co-led by Polaris Venture Partners and SV Life Sciences, both of whom were previous investors in Adimab.

“Since Adimab’s founding in 2007 we have experienced significant interest from both potential partners and investment groups,” said Errik Anderson, Vice President of Operations and Finance. “This financing, at a significant step up in valuation, allows us to confidently build the capacity to execute multiple programs with our partners.”

“Although the company was well capitalized, we felt that additional resources would allow us to more aggressively execute our hiring plan for 2008,” commented Tillman Gerngross, Ph.D., Chief Executive Officer of Adimab. “We have also accelerated our high throughput antibody expression and fermentation program, which is now expected to come on line in the second quarter of this year. Upon completion, we will be able to go from antigen to a panel of fully human antibodies in less than ninety days.”

“We have seen many antibody discovery platforms and felt that Adimab has the most compelling and seamless offering,” said Michael Ross, Ph.D., Managing Partner, SV Life Sciences. “Adimab has assembled a great team, has a thorough understanding of the IP, has made excellent progress on its technology, and has generated strong interest from several partners.”

“Tillman runs a lean team, but they consistently set high expectations and then over-deliver”, says Terry McGuire, Managing General Partner of Polaris Ventures. “The speed at which Adimab assembled a word class antibody discovery team and implemented its business strategy was impressive.”

About Polaris Venture Partners
Polaris Venture Partners is a partnership of experienced private equity investors, operating executives and entrepreneurs. The firm's mission is to identify, invest in and partner with seed, early stage, and middle market businesses with exceptional promise and help them grow into market-leading companies. The firm has over $3 billion under management, more than 20 investment professionals, and current investments in more than 75 companies.

About SV Life Sciences
SV Life Sciences is a venture capital fund providing financing to businesses at all stages of development across the human life sciences sector, including biotechnology, pharmaceuticals, medical devices and instruments, and healthcare information technology and services. SV Life Sciences currently manages or advises five funds with capital commitments of approximately $1.6 billion.

11.01.07
Adimab Annouces Scientific Advisory Board members

Lebanon, NH – November 1, 2007 – Adimab, Inc. today announced the initial members of the company’s scientific advisory board. Appointments include:

• Professor Stan Fields of the Howard Hughes Medical Institute and the University of Washington;
• Professor James D. Marks of the University of California; and
• Professor Bruce Tidor of the Massachusetts Institute of Technology

“We are delighted to benefit from the deep experience and counsel of these outstanding scientists, whose expertise relates well to Adimab’s efforts to utilize yeast as a single platform for antibody discovery, optimization and expression,” said Dane Wittrup, Adimab Chairman of the Scientific Advisory Board, Member of the Office of the Chief Scientific Officer, and Co-founder.

He continued, “Professor Fields, the most recent addition to the SAB, has made seminal contributions to yeast molecular biotechnology and brings a breadth of experience on protein interactions in yeast to our discovery effort. Professor Marks is a foundational pioneer in antibody engineering, and is doing some of the most exciting current work in the fields of tumor targeting and toxin neutralization. Similarly, Professor Tidor is a thought leader in the field of protein biophysics, and is developing some of the most advanced computational design algorithms available.”

09.17.07
Adimab and DNA2.0 Enter Exclusive Antibody Discovery Relationship

Lebanon, NH – September 17, 2007 – Adimab, Inc., a pioneer in the integration of antibody discovery, maturation and biomanufacturing and DNA2.0, Inc. (Menlo Park, CA), the largest U.S. supplier of synthetic DNA today announce a strategic alliance in the area of Antibody Discovery.

The two companies have entered into an exclusive agreement to jointly develop and produce proprietary antibody libraries that replicate the human immune system’s ability to produce antibodies against any target.

“We did extensive diligence on the leading gene synthesis companies and DNA2.0 had an impeccable reputation amongst its customers. Their ability to work with us on the integration of all aspects of gene synthesis and library design was a major driver in this relationship,” says Dane Wittrup, Adimab co-founder and Professor at MIT.

“Adimab brings a disruptive and novel approach to antibody discovery that has the potential to change the way we discover therapeutic antibodies in the future. We wanted to be part of that exciting development,” says Jeremy Minshull, DNA2.0 co-founder and President.

For more information, visit Adimab’s Partners (http://www.adimab.com/partners) or DNA2.0’s Partners (http//www.
DNA20.com/partners).

About DNA2.0
DNA2.0 is the largest US provider of synthetic genes, serving customers globally in the pharmaceutical and biotechnology industries as well as in academia. The company is also pioneering the application of machine learning to commercial protein engineering through their ProteinGPS™ platform. For more information please visit www.DNA20.com.

07.26.07
Adimab Acquires Rights to Genetastix Yeast Antibody Patents

Lebanon, NH – July 26, 2007 – Adimab, Inc., a pioneer in the integration of antibody discovery, maturation and biomanufacturing, announces the acquisition of the Genetastix (Palo Alto, CA) patent portfolio. Under the agreement the two companies have entered into an exclusive agreement by which Genetastix will assign all its method patents related to antibody discovery in yeast to Adimab, Inc. The financial terms of the agreement were not disclosed but are consistent with Adimab’s business model of reducing the excessive royalty stacking associated with current antibody discovery platforms.

“Genetastix was an early pioneer in yeast-based antibody discovery and we felt that their strong IP position in yeast based antibody discovery and library design would complement our scientific and patent strategy,” says Tillman Gerngross, Adimab co-founder, and CEO.

Lead scientist and founder of Genetastix, Li Zhu, explains, “seeing how fast the Gerngross/Wittrup team was moving their antibody discovery platform into practice, we felt that they will be the team that will make human antibody discovery in yeast a commercial reality. We were excited to join their effort.” Li Zhu will continue to serve as a consultant to Adimab.

07.20.07
Adimab, Inc. Secures Series A Financing from Polaris and SV Life Sciences

Lebanon, NH – July 20, 2007 – Adimab, Inc., a biotech startup developing an integrated yeast-based antibody discovery, maturation and biomanufacturing platform, announced today the closing of a $6.2mm Series A fi nancing.
The round was led by Polaris Venture Partners and SV Life Sciences who were joined by Angeli Parvi. In addition, Polaris Managing Partner Terry McGuire and SV Managing Partner Mike Ross joined Adimab’s Board of Directors.

Adimab was co-founded earlier in 2007 by Tillman Gerngross and Dane Wittrup, two pioneers in yeast biotechnology. Glycofi , the yeast glycoengineering company Dr. Gerngross co-founded, was recently bought by Merck for $400 million. Dr. Wittrup’s early yeast display technology was acquired by Abbott Laboratories in 2002.

“We believe Adimab’s integrated, yeast-based approach offers a compelling fully integrated next-generation antibody discovery and development platform,” stated SV Life Science’s Mike Ross. “In terms of speed to market, quality of antibody and freedom to operate, a yeast based approach has many advantages, and Tillman and Dane are the dream team of yeast engineering. If anyone is going to make this work, it’s them.”

Terry McGuire at Polaris added, “we’re hoping to apply some of the same business concepts to Adimab as we did to GlycoFi. We’re thrilled to be invested in this company and we’re hopeful to put at least $20-$50 million of Polaris’ money to work in Adimab.”

About Polaris Venture Partners
Polaris Venture Partners is a partnership of experienced private equity investors, operating executives and entrepreneurs. The firm’s mission is to identify, invest in and partner with seed, early stage, and middle market businesses with exceptional promise and help them grow into market-leading companies. The firm has over $3 billion under management, more than 20 investment professionals, and current investments in more than 75 companies.

About SV Life Sciences
SV Life Sciences is a venture capital fund providing financing to businesses at all stages of development across the human life sciences sector, including biotechnology, pharmaceuticals, medical devices and instruments, and healthcare information technology and services. SV Life Sciences currently manages or advises fi ve funds with capital commitments of approximately $1.2 billion.

07.09.07
Max Vasquez Ph.D. Joins Adimab as Senior Director of Computational Biology

Lebanon, NH – July 9, 2007 – Adimab, Inc., a biotech startup developing an integrated yeast-based antibody discovery, maturation and biomanufacturing platform, announced today the appointment of Dr. Max Vásquez as Senior Director of Computational Biology.

Dr. Vásquez had served in the position of Senior Director, Research at PDL Pharma, Inc., Freemont, CA, where he was involved in all efforts of antibody discovery, including antibody humanization, antibody engineering, bioinformatics, target validation, and preclinical development. More recently he founded Bocaracá Consulting, Palo Alto, CA a healthcare consulting practice focused on antibody discovery and engineering. Dr. Vásquez has over 15 years of experience in all aspects of therapeutic antibody discovery and development.

"We are delighted to have someone of Max’s stature join to head our Computational Biology efforts,” said Dane Wittrup, MIT professor and Adimab co-founder with Tillman Gerngross. “Max has a deep understanding of antibody sequence/function relationships, and broad experience in the computational design of human antibody pharmaceuticals. The computational capabilities he is developing will be a critical component of the Adimab discovery platform.”

“I am excited to join such an excellent team; Tillman and Dane laid the foundation for an antibody discovery platform where computational approaches have been integrated in a way that will add signifi cantly to the end result,” noted Dr. Vásquez. “The technology being developed has a real chance to transform the entire therapeutic antibody field.”